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Abstract:
Delivery of SiRNA with Drugs Targeting Polyamine Metabolism as Combinational
Cancer Treatment
Ao Yu, Ph.D.
University of Nebraska Medical Center, 2021
Supervisor: David Oupický, Ph.D.
Cancer has been a major public health issue worldwide for years and is the second
leading cause of death in the United States. Important barrier must be broken to extend
the life expectancy in every country. The standard care for cancer causes severe side effects
which affects patients’ physical health and quality of life. Polyamines are highly related
with the cell proliferation and apoptosis. Dysregulated polyamine metabolism in cancer
leads to increased polyamine concentration in neoplastic cells. Thus, polyamine
metabolism for cancer therapy can be an intriguing target. However, the heterogeneity
affecting key cancer pathways poses significant challenges for effective monotherapy.
RNA interference (RNAi) can knock down upregulated oncogene expression with
high specificity and selectivity. Among those, siRNA presents high potential as novel
therapeutic modality for cancer when properly delivered. This dissertation hypothesized
that polycation nanoparticles can be developed that regulate polyamine metabolism,
while simultaneously serving as siRNA delivery systems to achieve enhanced
combinational cancer therapy.

An introduction on polyamines and RNAi with their connections to cancer is
presented in chapter 1.
Chapter 2 reports on the development of hyaluronic acid-coated fluoroalkylconjugated polyamine prodrugs as siRNA delivery systems (HA@F-PaP/siPLK1) for
simultaneous targeting of polyamine metabolism and down-regulation of (polo-like
kinase 1) PLK1 expression. The ternary complex achieved reduced toxicity to the
membrane, improved gene silencing effect and selective targeting to tumor. The
combination of N1,N11-Bis(ethyl)norspermine (BENSpm) and siPLK1 demonstrated
superior apoptosis inducing effect in both colorectal cancer and pancreatic cancer. Finally,
orthotopic pancreatic model was developed for the evaluation of HA@F-PaP/siPLK1. The
biodistribution study showed selective tumor accumulation through CD44 targeting
effect and HA@F-PaP/siPLK1 significantly inhibited the tumor growth.
Chapter 3 reports on the folic acid conjugated, curcumin and siKras loaded
cationic lipoplex (2FLPC/siKras) as drug/siRNA combinational therapy against colorectal
cancer. The curcumin that targets multiple anti-cancer pathways is also involved in
polyamine metabolism regulation. Curcumin-loaded liposomes showed similar toxicity
and anti-migration effects as free curcumin. The folic acid on the lipoplex achieved
enhanced siRNA delivery. Finally, the combination of curcumin and siKras demonstrated
superior apoptosis inducing and anti-proliferation effect.
Chapter 4 reports on the attempts to synthesize different GSH responsive
polymeric norspermine prodrugs. Monomers were synthesized with methyl methacrylate

group, vinyl group and methyl acrylamide group with the self-immolative linker
conjugated with norspermine. The polymeric norspermine prodrug (PNP) were
polymerized

using

reversible

addition-fragmentation

chain

transfer

(RAFT)

polymerization. PNP showed excellent siRNA condensation ability with great siRNA
cellular uptake.
In chapter 5, summary and future directions are given.
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Chapter 1. Introduction

Cancer has been a major public health issue worldwide for years and is the second
leading cause of death in the United States. It was estimated 19.3 million new cancer cases
and almost 10.0 million cancer deaths occurred in 2020. Important barrier must be broken
to extend the life expectancy in every country.[1, 2] With the advances in early stage
detection and treatment, the number of survivors in the US continues to grow.[3]
However, the resistance of the cancer treatment is a common phenomenon. Despite some
of the cancers have strong resistance to treatment even without exposure to cancer
treatment, the initial favorable response in other cancer types tends to deteriorate leading
to cancer relapse and recurrence.[4, 5] Meanwhile, the standard care for cancer causes
severe side effects including nausea, pain, fatigue, and diarrhea, which affects patients’
physical health and quality of life.[6-8] The heterogeneity in the tumor due to the process
of gene mutation and tumor evolution has made the treatment of cancer even more
difficult.[9, 10] Recently, nanomedicine has been proved to improve efficacy with reduced
morbidity for the treatment of cancer.[11] The nanoparticles loaded with different
functional agents have been developed to simultaneously target different oncogenic
pathways in tumor to overcome the wall of resistance and improve therapeutic
outcome.[12, 13] Among these multifunctional nanoparticles, combination of polymeric
chemotherapeutic drug with RNAi as drug/RNA nanoparticles arose to be an effective
strategy for cancer therapy.[14-17]
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Polyamines are essential organic polycations involved in many fundamental
processes of cell growth and viability.[18, 19] Thus, depleting the cancer cell polyamine
concentration has been proven to be a promising strategy for improved cancer therapy.
[20, 21]

Recently, our group developed polymeric polyamine prodrug that can

simultaneously introduce the cancer cell polyamine depletion and deliver therapeutic
siRNA. Here, we will introduce different topics to understand the combination strategy
based on polyamine depletion and RNA interference.
1.1

Polyamine

Polyamines are aliphatic polycations, and include putrescine, spermidine and
spermine, ubiquitously present in all tissues and all cell types examined in plant and
animals.[22] The fact that the polyamines have been proposed to be included among the
list of Simple Universal Molecules essential for life proves the indispensable role of the
polyamines.[23] The content of polyamines in mammalian cells is necessary for a wide
range of cell functions including interaction with nucleic acid, protein synthesis, cell
proliferation, differentiation and apoptosis.[24-26]
1.1.1

Polyamine functions

Polyamines are involved in the stability of the nucleic acids. Polyamines interact
with genomic DNA and support the conformational arrangement.[27] The presence of
polyamines can stabilize the DNA duplex, specifically decrease the disassociation rate,
without changing the secondary structure of the DNA.[28] Similarly, polyamines improve
the thermal stability of DNA/RNA and RNA/RNA duplex by stabilizing the conformation
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toward A form.[29] Interestingly, at low polyamine concentration, spermidine and
spermine interact with DNA showing flower like conformation with high gene expression
while exhibited folded compact conformation at high polyamine concentration associated
with complete inhibition of gene expression.[30] Despite the direct stabilization of the
DNA, polyamines could also mitigate depurination, as lethal forms of damage to DNA,
through the polyamine stimulated synthesis of heat shock protein and antioxidant
protein.[31, 32]
The polyamines, mainly exists as polyamine-RNA complex, bind with RNA in a
sequence-selective fashion and induce changes in RNA structure in context-dependent
manners, which is distinctive from the divalent cations like Mg2+.[33, 34] Addition of
polyamines not only increased the activity of translation system and increased the total
protein yield but also decreased the optimal Mg2+ concentration which is necessary for the
protein synthesis.[35, 36] In a rabbit reticulocyte cell-free system, each polyamine
stimulated the synthesis of globin by six to eight fold at optimal concentration which is
consistent with the intracellular concentration.[37, 38] Polyamines are also essential for
some the synthesis of some proteins in eukaryotes. Polyamine modulon is referred as a
set of genes whose expression is enhanced at the presence of polyamines in the level of
translation.[39] The mechanism of the polyamine stimulated proteins expression is under
investigation but there are different hypotheses including stabilization of the bulged-out
region of double-stranded RNA in mRNA, and enhancing the ribosome shunting on the
5’-untranslated region (5’-UTR) mRNA.[40-43]
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Polyamines also play an indirect role in protein synthesis. Eukaryotic translation
factor 5A (eIF5A) has the unique amino acid hypusine with multiple functions in peptide
synthesis whose hypusine group is indispensable for peptide synthesis.[44, 45]
Spermidine acts as aminobutyl group donor for the post-translational modification of the
eIF5A by deoxyhypusine synthase (DHS), which is then activated by deoxyhypusine
hydroxylase (DOHH). Activated eIF5A may contribute to multiple functions but the most
known function is the contribution to the initiation of the peptide synthesis and elongation
of proline containing peptide.[45-49]
Due to the crucial roles of polyamines in cells, the polyamine concentration was
tightly controlled by key enzymes in biosynthesis and catabolism.
1.1.2

Polyamine metabolism and transport

Intracellular polyamines are tightly regulated through metabolic pathways,
import and export systems and compensatory mechanisms.[50] Scheme 1.1 depicts the
polyamine synthetic and catabolic pathways in mammalian cells.[20] The precursor of the
polyamines ornithine is produced by arginase 1(ARG1) as part of the urea cycle. The first
polyamine, putrescine, is synthesized by the first rate limiting synthetic enzyme ornithine
decarboxylase (ODC). Synthesis of spermidine and spermine is accomplished by
transferring aminopropyl group by spermidine synthase (SPDSY) and spermine synthase
(SPMSY) respectively. S-adenosylmethionine decarboxylase (AdoMetDC), as the second
rate-limiting polyamine biosynthetic enzyme, produces the decarboxylated Sadenosylmethionine (dcAdoMet) which is the aminopropyl donor required for the
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synthesis of spermidine and spermine. 5’-methylthioadenosine (MTA) is the product after
the donation of aminopropyl group from dcAdoMet. MTA is then converted by the 5’methylthioadenosine phosphorylase (MTAP) into adenine and 5-methylthioribose-1phosphate, latter can be salvaged into methionine through enzymatic steps. Adenine is
converted into ATP through multiple steps. First phosphoribosyltransferase (APRT)
transformed adenine into AMP with phosphoribosyl pyrophosphate (PRPP) as a
phosphoribosyl donor. Then subsequent phosphorylation is achieved by inorganic
phosphate groups (Pi). Salvaged methionine can combine with ATP to form AdoMet by
methionine adenosyltransferase 2 (MAT2). The synthesis of polyamines is not reversible,
but the interconversion of the polyamines can occur at the presence of catabolic enzymes.
The highly regulated rate-limiting catabolic enzyme spermidine/spermine N1acetyltransferase 1 (SSAT) catalyze the acetyl group from acetyl-CoA to spermidine or
spermine.[51] The acetylated polyamine can be exported or oxidized by polyamine
oxidase (PAOX) creating hydrogen peroxide and 3-acetylaminopropanal (3-AAP).
Spermine can be directly oxidized to spermidine by spermine oxidase (SMOX) to produce
3-aminopropanal (3-AP) and hydrogen peroxide. Polyamine catabolism prevents the
excessive polyamines in the cells, but the amount of reactive oxygen species may increase
causing the oxidative damage. SMOX, located in nuclear and cytoplasm, is more
responsible for the generation of the ROS and oxidative damage since PAOX locates in
peroxisome. Polyamine catabolism can be increased due to infection, cell damage which
produces ROS that could damage the DNA, proteins and other cell components.[52]
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Since the polyamines are positively charged at physiological pH, a transport
system must be applied for the uptake of exogeneous polyamines. However, the
polyamine transport system (PTS) remains elusive. But parameters about the PTS are
known as carrier mediated, time-, temperature- and concentration-dependent, energy
requiring, and saturable.[53] Some cell lines have a single transport system that uptake all
three polyamines while most of the cell lines contains two different PTS classified by
sodium dependency. Recently, ATP13A3 which is previously genetically linked with
pulmonary arterial hypertension is found to be a part of PTS that responsible for
putrescine uptake. ATP13A3 encodes P5B-ATPase, a P-type transport ATPase that could
be a candidate for PTS.[54]
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Scheme 1.1 Polyamine synthetic and catabolic pathways in mammalian cells
(Adapted from [20]).
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1.1.3

Self-regulatory mechanism maintaining polyamine homeostasis

The complication of the polyamine metabolism is confirmed more than in the
multi-step biosynthesis and catabolism. Polyamine self-regulatory system by regulation
of biosynthetic, catabolic, and regulatory proteins highlights the interplay of polyamines
and protein synthesis to maintain the polyamine homeostasis.
Synthesis of first polyamine putrescine by the first rate limiting synthetic enzyme
ODC plays a central role in the polyamine synthesis, which would, of course, be subjected
to extensive regulations. ODC is only catalytic active as a homodimer whose activity is
regulated mainly by antizyme isoform 1 (AZ1) and antizyme inhibitor (AZIN).[55, 56] The
interplay is shown in scheme 1.2.[57] Firstly, ODC dimer can decarboxylate the ornithine
which could be inhibited by AZ1 due to the higher monomer affinity compared with ODC
monomer. Then AZ1-ODC complex is degraded by proteosome 26S and AZ1 is recycled.
AZ1 can also inhibit the PTS to reduce the intracellular polyamine uptake. Increased
polyamines can stimulate the synthesis of AZ1 by +1 frameshift at the stop codon leading
to the translation. On the contrary, AZIN has higher affinity with AZ1 compared with
ODC monomer, releasing, and restoring the ODC activity. AZIN can be ubiquitinated and
degraded by proteasome. As a result, increased polyamines can downregulate the
transcription of ODC and AZIN.
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Scheme 1.2 Regulation of ODC expression by antizyme and antizyme inhibitors in
mammalian cells (Adapted from [57]).

Similar to ODC, AdoMetDC is also regulated by a variety of mechanisms. [58] As
shown in scheme 1.3, transcription of AdoMetDC gene and translation of its mRNA is
negatively regulated by spermidine and spermine. Peptide MAGDIS encoded by the
upstream ORF (in red) can also regulate the translation of AdoMetDC by impairing the
downstream translation when the polyamine concentration increases.[59] The AdoMetDC
mRNA encodes a proenzyme (π subunit) that undergoes a spontaneous reaction
generating pyruvoyl prosthetic group (Py-) with α and β subunits. The activation of the
proenzyme requires putrescine and incorrect protonation of the pyruvate group converts

10

Scheme 1.3 Regulation of AdoMetDC expression in mammalian cells (Adapted
from [58]).

it into Alanine (Ala-) group permanently inactivating the enzyme. The activated
AdoMetDC can then be used to dcAdoMet which is a substrate for the synthesis of
spermidine and spermine. When the spermidine and spermine are excessive, AdoMetDC
can be degraded by ubiquitin dependent proteolytic system which is increased by
spermidine and spermine.[60]
Increased intracellular polyamines leads to rapid synthesis of catabolic enzyme
SSAT, which is an important polyamine homeostatic mechanism.[61] SSAT is the smallest
protein in polyamine metabolism with a short half-life as only 15 mins.[62] Polyamines
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have been related with transcription, translational regulation and stability of SSAT.
However, the regulation mechanism between SSAT and polyamines are not clear. The
hypotheses of the autoregulatory mechanism include alternative splicing of its mRNA,
transactive of SSAT gene by transcription factor nuclear erythroid factor 2 (NRF2), release
of a translational repressor for initiation of SSAT protein synthesis and stabilization of
SSAT against degradation by the 26S proteasome.[61-66]
1.1.4

Polyamine and cancer

As mentioned before that polyamines are highly related with the cell proliferation
and apoptosis, it is not surprising that the polyamine metabolism is dysregulated leading
to increased polyamine concentration in neoplastic cells.[67-71] The relevance of
polyamines and cancer cell functions has been known for ages and multiple oncogenic
pathways have been identified to contribute to the polyamine metabolism
dysregulation.[71] The summary for the oncogenic pathways related to polyamine
metabolism is demonstrated in scheme 1.4.[72] First, as one of the earlies mutated genes
in cancer, the RAS genes family, HRAS, NRAS and KRAS, are collectively mutated in one
third of human cancers.[73] The mutated RAS promotes cell proliferation through
RAS/RAF/MAPK pathways which also activates ODC transcription and translation.[74]
Additionally, Mutated KRAS can inhibit the tumor-suppressor peroxisome-proliferatoractivated receptor-γ (PPARγ) which can activate SSAT transcription.[75] Transcription
factor MYC is overexpressed in many types of cancer that is necessary for cell growth.[76]
And expression of ODC is regulated by MYC transcription factor that binds with the
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promotor site in ODC gene (ODC1), leading to an increased ODC1 mRNA and ODC
protein, providing the necessary polyamines for proliferation. The MYC and ODC1 coamplification demonstrates the first targeted deregulation of an oncogenic transcription
factor to the polyamine oncogenic target ODC1 gene that codes ODC.[77] Other synthesis
genes including SRS that encodes Spd synthase and AMD1 that encodes AdoMetDC can
also be facilitated by a MYC.[72, 78] Phosphoinositide 3-kinase (PI3K) mutations is almost
ubiquitous in human cancer.[79] The signal pathway PI3K, protein kinase B (AKT) and
mammalian target of rapamycin (mTOR) regulate cell growth, differentiation, migration
and survival, as long as angiogenesis and metabolism including polyamine metabolism.
Activated PI3K in cancer cells revealed an amplified polyamine biosynthesis leading to
increased putrescine, spermidine, and MTA.[72, 80] Several proteins interact with mTOR
to form at least 2 distinctive complexes, namely mTOR complex 1 (mTORC1) and 2
(mTORC2).[81] Recent study has shown that mTORC1 can activate the production of
DCAdoMet and putrescine through the upregulation of AMD1 and ODC1. Also mTORC1
indirectly blocks the production of OAZ1 by blocking the mTORC2 activity which serves
as OAZ1 activator.[72] Since oncogenic genes have been related to the increased
intracellular polyamine concentration, it is reasonable to speculate that the tumor
suppressor genes would negatively downregulate the intracellular polyamines. As one of
the most important defenders against tumor development, p53 is now emerging as an
important gene in the response to and regulation of metabolic stress.[80] Recently, SAT1
that encodes SSAT is identified as transcription target of p53.[82] Adenomatous polyposis
coli (APC) is a suppressor gene that is commonly mutated in colorectal cancer. And the

13

Scheme 1.4 Oncogenic pathways regulating the polyamine metabolism (Adapted
from [72]).
loss of APC means the increased expression of MYC which will increase the transcription
of genes mentioned before. APC also regulates the expression of OAZ1 and mutated APC
will decrease OAZ1 contributing to increased ODC activity.[75]
Recent success of applying immunotherapy, specifically immune checkpoint
blockade, for multiple types of cancer therapy in clinical trials indicates the effectiveness
of using the immune system against cancer.[72] However, immune evasion and
suppression mechanism are the major obstacles for cancer immunotherapy.[83] And
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polyamines exert an immunosuppressive role, which are consistent with their
carcinogenetic role in cancer.[71] In glioblastoma massive infiltrated immunosuppressive
tumor associated myeloid cells (TAMCs) showed the upregulated polyamine
concentration in TAMCs buffered the low intracellular pH to support the survival of those
immunosuppressive cells in harsh acidic tumor microenvironment, but CD8+ T cells
cannot survive in the acidic microenvironment since the intracellular polyamine
concentration was not elevated in those immune effector cells.[84] Arginine, produces
ornithine at the presence of ARG1, is known to be important in immune system. Depletion
of arginine by ARG1 in immunosuppressor cells impairs T cell activity. Moreover,
amplified polyamine biosynthesis that consumes ornithine promotes the ARG1 activity in
tumor cells, which even deteriorate the arginine depletion. As a result, this can reduce the
immune response from T cells.[85, 86] Injured or dying cell release spermine and
increased spermine levels in inflammatory site negatively regulate macrophage activation
by restrain its innate immune response.[87] Similarly, spermine can protect mice against
lethal sepsis by weakening local and systemic inflammatory response.[88] These
mechanisms involved with polyamines could potentially be used by tumor for immune
evasion.[71]
1.1.5

Targeting polyamine metabolism for cancer therapy

With the functions of polyamines in cells and the convoluted relationships
between polyamines and cancer, targeting polyamine metabolism can be intriguing for
cancer treatment. One strategy is to target the two rate-limiting biosynthetic enzymes,
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ODC and AdoMetDC, that is upregulated in tumor.[89] The widely used ODC blocker, αdifluoromethylornithine (DFMO), irreversibly binds with ODC that induce cytostasis in
cancer cells.[90] Although the biosynthesis pathway in inhibited, the upregulation of PTS
that compensate the polyamine depletion effect and DFMO does not reduce spermine to
any great extent in mammalian cells. As expected, DFMO is not successful as an anticancer
drug. However, the success of DFMO for the treatment of parasitic infection does grant
the FDA approvement for the treatment of sleeping sickness caused by trypanosomes.[91]
Despite the fact that DFMO has limited polyamine depletion efficacy, studies have
demonstrated that when combined with other inhibitors DFMO could be used as
chemoprevention agent. Recently DFMO and non-steroidal anti-inflammatory drugs
(NSAIDs), sulindac, can prevent metachronous colorectal adenomas in low polyamine
intake group in phase III clinic trials.[92] The combination of DFMO and polyamine
transport inhibitor AMXT 1501 and trimer PTI can overcome the limit of DFMO
monotherapy. The combinational study termed as (polyamine blockade therapy (PBT))
not only blocks tumor growth but also promotes cancer immune responses by increasing
the granzyme B+, CD8+ T cells and decreasing immunosuppressive cells including
myeloid derived suppressor cells (MDSCs), Tregs and M2 microphages which is
consistent with the immunosuppressive role of polyamine.[85, 93, 94] The relieved
polyamine-mediated immunosuppression in tumor microenvironment also sensitized
4T1 mammary carcinoma and B16F10 melanoma to immune checkpoint inhibition, PD-1
blockade therapy.[95] Although DFMO irreversibly binds with ODC, other study
indicated

that

DFMO

can

also

inhibit

ARG1

activity

that

reverse

tumor
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immunosuppressive microenvironment by skewing myeloid cell polarization from M2 to
M1 phenotype and may be responsive for stimulating the tumor immune response.[86, 94]
Inhibition of AdoMetDC has also been an exciting target for anticancer therapy.
Methylglyoxal

bis(guanylhydrazone)

(MGBG)

and

4-amidinoindan-1-one

2’-

amidinohydrazone (SAM486A) are powerful inhibitors for AdoMetDC.[96] However,
severe toxicity hampered their use due to its anti-mitochondrial actions and other offtarget effects.[20] Alternatively, given the fact that MTAP is critical for methionine
metabolism, targeting MTAP like prostate cancer can be a promising strategy and
blocking MTAP can inhibit prostate cancer growth.[97]
Sustained cell proliferation in environment rich in inflammatory cells, growth
factors and DNA damaging agents potentiate neoplastic risks.[98] Infection and
inflammation stimuli induce the expression of both SSAT and SMOX which are the two
conditions associated with tumor. Increased ROS production caused by polyamine
catabolism may disrupt proper signaling and damage DNA leading to DNA
instability.[99] Thus, similar to NSAIDs, inhibition of SSAT and SMOX can potentially
serve as chemoprevention. N1,N4-bis(2,3-butandienyl)-1,4-butanediamine (MDL 72527) as
both SMOX and PAOX inhibitor leads to decreased ROS generation, DNA damage and
tumor incidence in bacterium enterotoxigenic induced colon tumorigenesis.[100] The
structure of the compounds mentioned above is listed in Figure 1.1.
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Figure 1.1 Specific inhibitors of polyamine metabolism and transport system.

Direct inhibition in polyamine synthetic enzymes as monotherapy for cancer
proves to be ineffective due to self-regulatory mechanisms that eventually maintains
polyamine homeostasis which reduces the therapeutic effect against cancer. To overcome
the problem, polyamine analogues are developed to deplete the intracellular polyamines
through the same self-regulatory mechanism.[101] To achieve this, multiple requirements
have to be met. First, the polyamine analogues are uptake by PTS which function as
competitive inhibitor; downregulate biosynthetic enzymes and upregulate catabolic
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enzymes so the intracellular polyamines are reduced; cannot be easily catabolized; do not
have any growth stimulation functions like natural polyamines. Three generations of
analogues that mimic the natural polyamines are developed and exploited to fulfil those
requirements.[20, 21, 70, 102, 103] The first generation is the symmetrically substituted
analogues like N1, N11-bis(ethyl)norspermine (BENSpm) also known as DENSpm and N1,
N12-bis(ethyl)spermine (BESpm). BENSpm demonstrated excellent anticancer efficacy in
several preclinic model including melanoma, lung cancer, colorectal cancer, pancreatic
cancer and prostate cancer.[104-108] With the promising preclinical results, BENSpm is
highly tolerable yet ineffective in clinical trials.[109] One possible reason for the difference
between clinical study and preclinical study could be the short half-life of the BENSpm as
0.5 h-3.7 h depending on the dose.[110] However, since the tumors were not collected
from patients, the actual amount of BENSpm in tumor and the polyamine depletion
efficiency was unknown. Then the second generation and third generation emerge for the
improvement based on the first generation. The second generation are the asymmetrical
substituted alkylamines on the end of the norspermine or spermine.[111] As expected, the
synthesis of those asymmetric compounds can be more difficult, and the first
unsymmetric polyamines are N1-propargyl-N11-ethylnorspermine (PENSpm) and N1cyclopropylmethyl-N11-ethylnorspermine (CPENSpm). Those asymmetric analogues
demonstrated more activity than BESpm and cell-type specific cytotoxicity associated
with high induction of SSAT.[112] Although those compounds are less successful than
BENSpm, asymmetric analogues hold great potential for further functionalization with
other moiety to increase targeting, half-life and so on. The third generation are the
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conformationally restricted analogues with central carbons being rotationally restricted
by introducing double bond or cyclic moieties.[113] PG-11047, also known as CGC-11047,
is designed based on BESpm with a double bond in the central 4-carbon bridge. Another
representative compound CGC11093 is designed by introducing a cyclopropyl bond into
N1, N14-bis(ethyl)homospermine (BEHSpm). Both compounds demonstrated increased
anti-proliferative activities with reduced toxicity. A phase I clinical trial demonstrated the
safety of the PG-11047.[114] And like BENSpm, the PG-11047 were also ineffective in
clinical trials; no activity better than stable disease is reported. The structures of the
polyamine analogues are listed in figure 1.2.

Figure 1.2 Three generations of polyamine analogues.
The discovery of BENSpm in 1990s made it clear that polyamines play an
important role in tumor and targeting polyamine metabolism is a promising and safe
strategy for cancer therapy. After that numerous molecules were synthesized to fulfil
those difficult requirements, polyamine analogues still have a long way to live up to their
promises.
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1.2

RNAi
Approximately 50 years since the visionary scientists demonstrated the concept of

genetic modification might effectively treat multiple severe human diseases, gene therapy
is now considered as a promising treatment strategy with successful clinical trials
worldwide.[115, 116] Initially, cells are transduced with recombinant virus to deliver
genetic materials encoding protein that is missing or defective to restore the original
function.[117, 118] Unlike the restore of function, there is also a increasing interest in
developing therapies based on inhibition of function using RNA interference (RNAi).[119]
In 1993, RNAi was first discovered in Caenorhabditis elegans, which involves in targeted
transcript cleavage and degradation following the binding of the sequence specific small
interfering RNA (siRNA) as an post-transcriptional regulation mechanism.[120, 121]
Actually RNAi regulates mRNA stability and translation in nearly all human cells and has
been harnessed as a genetic manipulation tool by introducing RNAi reagent into cells or
whole organism.[122, 123] The findings that siRNA can elicit RNAi in mammalian cells
and that the expression of the targeted gene can be knocked down with high specificity
and selectivity present the potential of RNAi as novel human therapy strategy.[124-126]
1.2.1

Mechanism of RNAi

RNAi are powerful gene silencing tools including small interfering RNA (siRNA)
and microRNA (miRNA).[15] The process of the gene silencing by siRNA and miRNA is
described in scheme 1.5.[127]
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MiRNA can be first transcribed from non-coding genome to be a long noncoding
RNA known as primary miRNA (pri-miRNA) which is processed by Drosha, a
ribonuclease III enzyme, for export from nucleus via exportin 5. The exported pri-miRNA
is further processed by cytoplasm Dicer into functional miRNA duplex with imperfect
stem-loop structure.[128] MiRNA is loaded into argonaute (AGO) family protein to form
miRISC and the passenger strand is discarded. MiRISC is guided by the remaining guide
strand to target mRNA through partially complementary binding which enables
inhibition multiple intracellular mRNA with one miRISC. Due to the fact that the miRISC
has no activated AGO2, the targeted mRNA is silenced via translational repression,
degradation by deadenylation, decapping or exonuclease action.[129] Additionally, antimiRNA consists of antisense oligonucleotides that sequester mature miRNA and
functions of targeted miRNA can be inhibited.[130, 131]
On the other hand, exogenous double-stranded RNA (dsRNA) or short hairpin
RNA (shRNA) could be introduced in mammalians and cut by Dicer to produce a smaller
dsRNA known as siRNA.[132, 133] SiRNA is introduced into the cells to transiently
suppress the expression of target gene through the formation of RNA-induced silencing
complex (RISC).[134, 135] SiRNA is loaded onto the active AGO which cleaves the
passenger strand while the guide strand guides the activated RISC to the target mRNA
based on full complementary sequence recognition and the mRNA is cleaved by AGO2
and exonuclease.[127, 136-138] The silencing potency of siRNA is transient since cell
division can dilute the siRNA. To circumvent this limit, short harpin RNA (shRNA) is
designed for DNA integration with virally produced vectors. The shRNA sequence is then
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exported to cytosol and go through the process mentioned above for mRNA
degradation.[128, 139]

Scheme 1.5
[127]).

Gene silencing mechanisms of siRNA and miRNA (Adapted from
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1.2.2

RNA delivery

RNAi aims to influence gene expression in living organism to treat or prevent
disease by the delivery of therapeutic RNA.[140, 141] Compared with traditional small
therapeutic molecules that can only target a certain classes of proteins, RNAi offers the
advantage of targeting the non-druggable mutations.[127] Long dsRNAs, as powerful
gene manipulation tools, are used to trigger RNAi in fungi and plants which,
unfortunately, activates interferon (IFN) pathway as part of the anti-viral mechanism in
innate immune response in mammalian cells, which ultimately leads to cell death.[142,
143] Application of smaller dsRNA can bypass the dsRNA sensor of innate response since
protein kinase R (PKR), as the sensor of IFN response to non-self dsRNA in mammals, is
not activated by dsRNA shorter than 30 bp.[144] Thus, introduction of synthetic siRNA
along with a proper material, skipping the Dicer processing, can result in effective RNAi
without activation of IFN pathways.[124, 129, 145, 146] However, the hydrophilicity of
large size of RNA prohibit them from crossing the cell membrane and proves challenging
to utilize in vivo due to short half-life, susceptibility to RNases, poor chemical
stability.[147, 148] Moreover, the therapeutic RNA must be accumulated at correct site
and corrected cells must be present in large quantity to reverse the condition while survive
the immune recognition.[116, 149] Thus, viral vectors and non-viral vectors of therapeutic
RNA have been developed to overcome those challenges.[150, 151] The advantage of viral
vectors is the high efficiency for delivering the genetic cargos with little modifications on
their original genomes.[152] Nonetheless, immunogenicity and insertional mutagenesis
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cause concerns about the application viral vectors in clinical application.[153, 154] On the
contrary to the viral vectors, non-viral materials, continue to be an attractive alternative
to viral vectors due to their safety, versatility and ease of preparation and scale up.[125,
155] Those delivery systems, specifically cationic polymers and lipid formulations,
contain ionic complexes and assembly mainly through electrostatic interaction between
the cationic amine groups and anionic phosphate groups in nucleic acids, which
ultimately form as polyplex or lipoplex nanoparticles.[156, 157] The expansion of
nanoparticles for the delivery of nucleic acids has been an exciting cancer therapy strategy
with potentially higher therapeutic efficacy and lower toxicity.[158]
1.2.3

Systemic RNAi delivery of nanoparticles for cancer

Due to the instability and size (<10nm) of the naked RNA, systemic injection of
RNA leads to degradation of the RNA in serum or fast elimination by kidney.[159, 160]
Although application of nanoparticles for RNA delivery does improve the stability and
circulation time of RNA, there are several barriers before the nanoparticle finally reaches
to tumor. The nanoparticles once intravenously injected will navigate in the bloodstream
avoiding uptake by phagocyte, aggregation, kidney filtration or degradation.
Phagocytosis as immunological barrier can remove foreign but therapeutic materials for
protection purposes.[161] Then nanoparticles travel to the lung where contains first
capillary and large or highly positively charged particles will be trapped in lung.[162] If
the nanoparticles leave the lung to the systemic circulation, extravasation from the
bloodstream to the normal tissues poses a significant hurdle due to the endothelial
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barrier.[163] Generally, molecules with a size over 5 nm cannot readily cross capillary
endothelium in normal tissues and will remain in circulation before clearance. Specially,
due to the imbalance between pro- and anti-angiogenetic signaling, solid tumor creates
an abnormal vascular network characterized by dilated, tortuous and disorganized blood
vessel.[164] The disrupted tumor vasculature leads to high vascular permeability and
blood leakage.[165] Therefore, nanoparticles with long circulation time can preferably and
selectively leak into the tumor tissue and retained in the tumor bed due to reduced
lymphatic drainage. This process is termed as enhanced permeability and retention (EPR)
effect.[166] After the extravasation of the nanoparticle, it must diffuse in the extracellular
matrix (ECM) before it is uptake by cancer cells. The diffusion process of nanoparticles in
ECM can be restricted by dense and stiff integrated macromolecular network bound by
multiple components in ECM.[167-169] Once the nanoparticles were uptake by targeted
cells, particles have to escape from degradation in acidic compartments and nuclease in
endo/lysosomal environment to reach cytoplasm and release the therapeutic RNA to for
subsequent gene expression regulation processes.[160, 170] It is through those barriers can
the RNAi delivery process completed and any inefficiency at any particular stage can lead
to marginal or no gene silencing activity. Therefore, the design of the nanoparticles must
be precisely engineered to overcome those delivery challenges to the widespread of RNAi
as cancer therapy.[160]
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1.3

Apoptosis

Cell death is essential for life.[171] Apoptosis is the evolutionary conserved,
programmed process of cell death. This complicated process is involved in coordinated
activation and execution of multiple subprograms. As important as cell proliferation and
differentiation, cell apoptosis can tightly control the numbers of cells or size of tissues and
protect from the rogue cells that threatening the homeostasis.[172, 173] Reasonably,
defects in apoptosis due to oncogenic mutation is a crucial step toward tumorigenesis,
potentially leading to tumor initiation, progression and metastasis.[174] The fact that
majority of the chemotherapeutic agents and radiational therapy utilize apoptotic
pathways to induce cancer cell death further stresses significance in the understanding
the signaling and pathways of apoptosis for the treatment of cancer.[175]
1.3.1

Apoptosis mechanism

The process of apoptosis was first discovered in 1972 that described a common
type of cell death that shared many stereotypic morphological features in various tissues
and cell types, which were distinct from pathological or necrotic cell death.[176, 177] The
morphological characteristics include cell shrinkage, membrane blebbing chromatin
condensation, and nuclear fragmentation which is caused by a set of cysteine proteinase,
termed as caspase.[172, 178] Caspases are widely expressed inactive proenzyme and once
activated, can often activate other procaspases inducing the protease cascade.[179] Two
major apoptotic pathways have been discovered: the intrinsic pathway and extrinsic
pathway (scheme 1.6).[180]
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The intrinsic pathway is initiated by mitochondrial outer membrane
permeabilization (MOMP) resulting from cell stress, overload of Ca2+, DNA damage, cell
cycle arrest and so on. [181] BH3-only family proteins can be stimulated which activates
proapoptotic effectors BAX and BAK. Then the pro-apoptotic factors (apoptogens)
including cytochrome c are released from intermembrane mitochondria space. When in
cytosol, cytochrome c interacts with adapter molecule apaf-1 and dATP leading to
oligomerization into apoptosome. Caspase 9 is recruited and activated by apoptosome,
followed by activation of downstream effector caspase 3, 6 or 7, which result in the orderly
death of the cell through controlled proteolytic processing of various downstream
targets.[182, 183] Indirectly but importantly, second mitochondria-derived activator of
caspases (SMAC) released from mitochondria blocks caspase inhibitors X-linked inhibitor
of apoptosis protein (XIAP or IAP3).
The extrinsic pathway is triggered by activation of death receptors in tumor
necrosis factor (TNF) receptor superfamily containing intracellular death domain
(DD).[181, 184] The best-characterized death receptors include Fas (APO-1/CD95), TNF
receptor 1 (TNFR1), DR3, DR6 TNF-related apoptosis-inducing ligand-receptor 1 (TRAILR1) and TRAIL-R2.[185] Activation of death receptors, Fas for example, by their ligands
results in recruit of caspase 8 or 10 into death induced signaling complex (DISC).
Activated caspase 8 can activate caspase 3, 6 or 7 for apoptosis and/or generate of tBID
triggering intrinsic pathways and magnifying the apoptotic response.[171, 180, 183]
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Scheme 1.6 Mitochondria mediated intrinsic pathway and receptor mediated
extrinsic pathway (Adapted from [180]).

As mentioned before, apoptosis is essential for homeostasis in body, but in cancer,
defects of apoptosis due to mutations greatly disturb the balance between cell division
and cell death.
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1.3.2

Apoptosis evasion in cancer

Theoretically, cancer cells are more susceptible to apoptosis due to growthderegulating mutations, intracellular oxidative stress. However, many anti-apoptotic
pathways keep the cancer cells safe from apoptosis, sustaining cancer growth (Scheme
1.7).[186] For example, the intrinsic pathway is dominantly controlled by B-cell lymphoma
2 (Bcl-2) family with pro-apoptotic and anti-apoptotic proteins.[180] There are three
subgroups: (1) proapoptotic Bax family (BOK, BAX and BAK), (2) antiapoptotic Bcl2
family (BCL-2, BCL-xL, BCL-w, Bfl-1 and Mcl-1) and (3) proapoptotic BH3-only family
(BID, BIM, BAD, p53 upregulated controller of apoptosis (PUMA) and NOXA).[180, 187]
Overexpression of anti-apoptotic proteins or reduced expression of pro-apoptotic proteins
or combination of both leads to the dysregulated apoptosis. The guardian of the genome,
tumor protein 53 (TP53 or p53) has been linked to more than 50% of human cancer. TP53
is a key suppressor protein with a diverse range of functions including pro-apoptosis
while mutation of TP53 leads to tumor progression.[188, 189] The inhibitor of apoptosis
proteins (IAP) are endogenous inhibitors of caspases by promoting degradation of active
caspase or blocking the caspase from its substrates and dysregulated IAP expression has
also been reported in many cancers. Similarly, reduced caspase activity or impaired
extrinsic receptors signaling pathways can lead to evasion of apoptosis.[189-193]
The most obvious strategy for cancer therapy is to target the pathways that
suppress cancer death, especially the anti-apoptotic pathways. However, it is likely that
cancer cells employ numerous mechanisms to evade the apoptosis. Providing the
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Scheme 1.7 Mechanism contributing apoptosis evasion and carcinogenesis (Adapted
from [186]).
complication of the anti-apoptotic mechanism and unknown pathways, applying agents
that can simultaneously hit multiple oncogenic targets to induce apoptosis may deliver
the best therapeutic outcome for cancer therapy.
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Chapter 2. Hyaluronic acid coated perfluoroalkyl conjugated polyamine prodrug
nanoparticles as siRNA delivery systems for the treatment of peritoneal cancers

2.1

Introduction

RNA interference (RNAi) is a novel therapeutic modality for the treatment of
cancer.[194] The clinical translation of the RNAi technology requires the development of
effective delivery vectors due to unfavorable biopharmaceutical properties of small
RNAs.[147, 195] Despite the clinical success of RNAi in hepatic delivery, the ability to
deliver RNA to distant tumors remains an area with the need for great improvement to
maximize the clinical potential of the RNAi technology.[196] Delivery of RNAi agents
such as siRNA can be achieved by viral or non-viral vectors. The use of cationic non-viral
vectors that utilize the advances in nanotechnology have been an attractive strategy due
to their versatility and relative anticipated safety.[125, 155, 197]
Multiple strategies have been developed to improve the RNA delivery efficacy by
non-viral vectors. Conjugation of hydrophobic moieties to polycations is a widely used
method to improve the RNA delivery efficacy.[198-200] The potential interaction of the
hydrophobic moieties with lipids and lipoproteins in serum and in cell membranes may
cause disruption of polycation/siRNA nanoparticles (polyplexes) or non-specific cell
damage.[200, 201] Additionally, the functionalization of the polymers with other
polymers, peptides or lipids may improve the transfection efficiency and biocompatibility
to some extent; the resulting materials are still not enough to be used in clinicals.[202]
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Fluorine, absent in biological system, is widely used for modification of
drug, biomacromolecules. Fluorocarbons are both hydrophobic and lipophobic
and thus exhibit high tendency for phase separation in both polar and non-polar
environments. Despite the low affinity of the fluorous chain for hydrocarbon chain,
the amphiphilic fluorous compounds have high affinity to cell membrane which
mainly contains amphiphilic phospholipids.[203] Introduction of perfluoroalkyl
moieties has been explored as a way of improving transfection efficacy of gene and
siRNA delivery systems.[202, 204] Additional studies also demonstrated that
perfluoroalkylated polycations can improve mucus penetration, cellular uptake
and biocompatibility.[205-207] [203]Inspired by the unique features of the fluorine,
we believe that conjugation with perfluoroalkylated promises a safer and more
efficient intracellular RNA delivery.[206-208]
The heterogeneity affecting key cancer pathways poses significant
challenges for effective cancer monotherapy.[209-211] Combination drug/siRNA
therapy approaches emerged as an excellent anti-cancer strategy due to their
different but potentially cooperative molecular mechanisms targeting multiple
cancer-associated pathways.[212] Cellular polyamine metabolism represents such
a suitable target for combination therapies. The naturally occurring polyamines,
putrescine, spermidine, and spermine are ubiquitously present in all human
tissues and all cell types.[22] Polyamines in mammalian cells are necessary for a
wide range of cellular functions, including cell proliferation and apoptosis.[26, 75]
The polyamine concentrations are tightly controlled by key enzymes and the
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polyamine transport system.[20] The relevance of polyamines in cancer has been well
known. Multiple oncogenic pathways have been identified to contribute to the polyamine
metabolism

dysregulation

in

cancer

cells,

leading

to

increased

polyamine

concentration.[71] With the functions of polyamines in cells and the convoluted
relationships between polyamines and cancer, targeting polyamine metabolism is a
rational target for cancer treatment. Many compounds have been developed targeting the
polyamine metabolism to deplete the intracellular polyamine concentrations.[89, 103]
N1,N11-bis(ethyl)norspermine (BENSpm) is one of the most successful polyamine
analogues that demonstrated excellent anticancer efficacy in multiple preclinical models,
including colorectal cancer and pancreatic cancer.[107, 108] By inducing the expression of
spermidine/spermine N1-acetyltransferase (SSAT) and spermine oxidase (SMOX),
BENSpm down-regulates polyamine biosynthesis and highly induces polyamine
catabolism, which leads near total polyamine depletion and apoptosis via the interactions
with apoptosis protein regulators and generation of reactive oxygen species.[107, 213-215]
Unfortunately, even though BENSpm monotherapy was well tolerated in clinical trials,
its efficacy was underwhelming.[109]
PLK1 is a serine threonine kinase required for regulation of mitosis that is
overexpressed in many types of cancer, including colorectal and pancreatic cancers.[216218] The overexpression of PLK1 correlates with tumor progression and low survival rate
implying a promising target for cancer therapy.[219]
In this study, we report polymeric prodrug based on BENSpm containing
perfluoroalkyl moieties (F-PaP) as a novel drug/siRNA delivery system (F-PaP/siPLK1).
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The resultant nanoparticles have been coated with hyaluronic acid (HA) to
improve stability and achieve targeting to CD44.[220, 221] We hypothesized that
the HA coated prodrug nanoparticles can effectively deliver siRNA to silence
expression of PLK1 and achieve enhanced antitumor activity through co-operative
apoptosis inducing effect on polyamine catabolism and PLK1 cell cycle arrest.
2.2

Results and discussion

2.2.1

Preparation and characterization HA@F-PaP/siRNA nanoparticles

The presence of four secondary amines in BENSpm inspired us to design a
polycationic BENSpm prodrug (PaP) for nucleic acid delivery.[222, 223] In order to retain
the pharmacological effect on polyamine metabolism in cancer cells, BENSpm had to be
released in unmodified form from the polymeric prodrugs.[224] To achieve the goal, we
synthesized PaP using self-immolative disulfide linker which can readily release BENSpm
upon reaction with intracellular glutathione (GSH).[223] The original PaP design,
however, lacked sufficient stability for use in systemic delivery and had to be used only
with intratumoral injection. To enhance the stability, safety, and improve siRNA delivery
efficacy, perfluoroalkyl groups could be introduced into the polymer. Based on prior
studies, heptafluorobutyl (HFB) moieties provided strong effect on siRNA transfection
efficacy in vitro[204, 225] and were thus used to modify PaP to prepare F-PaP. While direct
acylation of the secondary amines in BENSpm with heptafluorobutyric acid or anhydride
would be the easiest approach, such strategy would lead to formation of stable amide
bonds between HFB and BENSpm, thus compromising the anticancer activity of the

35
polyamine analog.[226] As an alternative, we modified tris(2-aminoethyl)amine (TAEA)
with the HFB moiety (HFBTA) and used the compound to directly copolymerize with
BENSpm

during

the

step-growth

polymerization

(Scheme

2.1).

During

the

polymerization, BENSpm, TAEA, and HFBTA were reacted with bis(2-hydroxyethyl)
disulfide (BHED) with its hydroxyl groups activated with carbonyl diimidazole (CDI).
Control PaP without HFB was also synthesized. The polymers were characterized by 1Hand

F-NMR. We determined 27 wt% and 30 wt% of BENSpm in PaP and F-PaP,
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respectively. The F-PaP contained 5.5 wt% of fluorine as quantified by 19F-NMR (Figure
2.2).

Figure 2.1 Synthesis scheme of PaP and F-PaP.
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Figure 2.2 NMR Characterization of PaP and F-PaP.
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In cancer cells, overexpressed GSH can cleave the disulfide bond and expose the
thiol group which attacks intramolecular carbamate group, releasing the free
BENSpm.[223] Hence, the release kinetics of BENSpm was evaluated by HPLC using
dithiothreitol as the reducing agent as described previously.[223, 227] Plotting the
results as the percent BENSpm release against degradation time indicated the
degradation followed first-order kinetics with the rate constant as 0.199 h-1 (half-life 3.5
h) and 0.174 h-1 (half-life 4.0 h) for PaP and F-PaP , respectively. (Figure 2.3 A). This
suggested that the prodrug nature of F-PaP is preserved, and the presence of the HFB
moieties has only minor slowing effect on the rate of disulfide cleavage.
Binding of siRNA with the synthesized prodrugs was evaluated by a gel
retardation assay. Both polymers achieved complete encapsulation of siRNA at
polymer/siRNA w/w ratio of 4 and above (Figure 2.3 B and C). Hydrodynamic size and
zeta-potential was characterized by dynamic light scattering in 10 mM HEPES. Overall,
the sizes of the nanoparticles were about in nanometer size with strong positive charge.
At w/w = 6, both polymers condensed with siRNA and formed uniform particles with
spherical morphology (Figure 2.3 D-I).
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Figure 2.3 Characterization of PaP and F-PaP formulations. (A) BENSpm release
kinetics of PaP and F-PaP in 100 mM DTT. (B) Free RNA % of two polymers at
different w/w ratio. (C) Gel retardation study of two polyplexes at different w/w
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w/w ratio. (E) and (H) Zeta-potential of nanoparticles. (F) and (I) Size distribution
and TEM image of PaP/siRNA and F-PaP/siRNA (w/w=6).
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One strategy to stabilize cationic nanoparticles carriers is to coat them with anionic
molecules. HA is a polyanionic polysaccharide which could be absorbed to the cationic
nanoparticles through electrostatic interactions for improved stability.[228] After coating
with HA, the size varied at different w/w ratio and the zeta-potential reversed to negative
values, indicating the successful formation of the ternary complex with a spherical
morphology (Figure 2.4 A-C). Potential release of siRNA by HA was studied but no
significant amount of free siRNA was observed after the HA coating, which indicated that
HA was not strong enough to release siRNA from polyplex (Figure 2.4 D).
To confirm the improved stability, the nanoparticles were incubated in heparin
and 10% FBS. Coating the nanoparticles with HA improved their stability against heparin
with only about 20% siRNA released when incubated with 400 µg/ml heparin (Figure 2.4
E). Serum contains negative charged proteins that can bind with the cationic nanoparticles,
leading to increased size. The colloidal stability of the nanoparticles against negative
charged proteins was evaluated in a 10% FBS solution. F-PaP/siRNA and HA@FPaP/siRNA showed different sizes the moment the FBS was added and the size of HA@FPaP/siRNA was around 200 nm after 16 h incubation while F-PaP/siRNA showed more
than 500 nm (Figure 2.4 F). This result also indicated the successful coating of the HA.
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The cleavage of the disulfide bond not only releases BENSpm but also causes the
disintegration of the nanoparticles leading to the release of the siRNA since free BENSpm
cannot condense siRNA. To verify the release of the siRNA, 20 mM GSH was applied to
degrade the polymer. Compared with groups without GSH, polymers lost their siRNA
condensation ability due to the degradation (Figure 2.5 A). We also validated the
degradability of the HA-coated nanoparticles. Incubation in 20 mM GSH, the siRNA was
released from the HA@F-PaP/siRNA demonstrating the reversible siRNA condensation
even after coated with HA. Additionally, no RNA was released after coating the HA again
showing that HA at this concentration was not enough to release the condensed siRNA
(Figure 2.5 A). We also evaluated the light scattering intensity of the nanoparticle after
incubation with 20 mM GSH, which had decreased significantly indicating the
degradation of the nanoparticles (Figure 2.5 B). The TEM study showed the swelling and
loosening of the structure for remaining particles indicating the successful degradation of
HA@F- PaP/siRNA (Figure 2.5 C).
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2.2.2

Reduced non-specific toxicity and improved cellular uptake in F-PaP/siRNA
Cytotoxicity of polycations is related to several key factors including charge

density, degradability, and hydrophobicity. By reducing the number of exposed positive
charges, non-specific cell membrane damage of cationic polymers is reduced.[229, 230]
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Thus, cell viability of both polymers was evaluated in three different cell lines by
CellTiter-Blue assay. The cells were incubated at different concentrations and IC50
calculated. The IC50 of F-PaP (IC50=26.8 µg/ml, 22.4 µg/ml, and 38.4 µg/ml respectively)
was higher than PaP (IC50=17.5 µg/ml, 15.9 µg/ml, and 26.5 µg/ml) indicating the reduced
cytotoxicity after incorporating the HF to the polymer in HCT116, CT26 and KPC8060 cell
lines (Figure 2.6 A and B). To confirm that the reason of reduced toxicity is due to the
reduced cell membrane toxicity, LDH assay was used to evaluate the integrity of the cell
membrane. Three cell lines were incubated with the polymers at the same BENSpm
equivalent concentration for 1h and LDH activity in the medium was quantified according
to the manufacturer’s protocol. As expected, BENSpm showed equivalent cell membrane
toxicity as PBS indicating the safety of utilizing this agent for cancer treatment. PaP
polymer and PaP condensed with negative control siRNA (siNC) PaP/siNC showed
significantly higher medium LDH activity indicating strong non-specific membrane
damage compared with free F-PaP and F-PaP/siNC (Figure 2.6 C).
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Recently, there were studies showing that the presence of perfluoroalkyl
moieties can drastically improve siRNA delivery efficiency.[202, 231] Thus, we
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want to verify the improved cellular uptake by using the fluorescently labeled siRNA. FPaP/siRNA showed about 2-fold increase in mean fluorescence intensity (MFI) compared
with PaP/siRNA in all three cell lines indicating the advantage of HF conjugated polymers.
F-PaP/siRNA w/w = 6 showed significantly higher uptake compared with w/w = 4 so this
ratio was selected for further study (Figure 2.7 A). Then confocal laser scanning
microscopy (CLSM) was applied to visualize and further confirm the improved siRNA
delivery. There was obviously more Cy5.5-RNA (Red) signal in F-PaP/siRNA group in all
three cell lines demonstrating improved cellular efficacy (Figure 2.7 B).
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2.2.3

Enhanced siRNA delivery of HA@F-PaP/siRNA
Besides improved stability, HA has a high affinity for CD44 expressed on

cancer cells, and thus can further improve the efficacy of siRNA delivery of coated
nanoparticles.[232] We first evaluated the CD44 expression in three cell lines by
immunofluorescent staining. CD44 was highly expressed (~100%) in all these cell lines
(Figure 2.8 A and B). Then, we optimized the HA/polymer ratio based on the cellular
uptake of FITC labeled siRNA. At w/w = 0.1, the cellular uptake was 3-fold and 2-fold
higher than at w/w = 0.2 in HCT116 and CT26, respectively. The 0.1 ratio was selected for
further study (Figure 2.8 C and D).
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To confirm that coating with HA can improve the endocytosis, HA coated
nanoparticles with FITC labeled siRNA were incubated with cells for 4 h and flow
cytometry was used to quantify the fluorescent intensity. HA@F-PaP/siRNA were readily
taken up by HCT116, CT26 and KPC8060 cell lines with highest MFI compared with FPaP/siRNA indicating the advantage of coating HA for siRNA delivery (Figure 2.9 A).
Those results were further confirmed by CLSM and more Cy5.5 labeled siRNA (red) in
HA@F-PaP/siRNA group was observed in all cell lines which was consistent with the
results of flow cytometry (Figure 2.9 B).
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2.2.4

Enhanced siPLK1 delivery by HA@F-PaP/siRNA

51
Having confirmed that HA@F-PaP/siRNA can effectively deliver siRNA into the
cancer cells we then used siPLK1 (HA@F-PaP/siPLK1) loaded nanoparticles and siNC
loaded nanoparticles (HA@F-PaP/siNC) as negative control to evaluate the target gene
silencing. The expression of PLK1 mRNA was measured by qRT-PCR. The HA@FPaP/siPLK1 silenced more than 80% of PLK1 expression in HCT116, CT26 and more than
90% in KPC8060 cell lines. As expected, there was a significant difference between FPaP/siPLK1 and HA@F-PaP/siPLK1 indicating the advantage of HA coating for siRNA
delivery (Figure 2.10 A).
Expression of PLK1 is crucial for inducing the G2/M transition in cell cycle and
knockdown of PLK1 by siRNA leads to accumulation of cells in G2/M phase.[233] The
ability of the nanoparticles to induce cell cycle arrest was tested by flow cytometry.
Compared with other groups, HA@F-PaP/siPLK1 increased about 30% cell population in
G2/M phase and decreased the cells in G0/G1 and S phases in all three cell lines (Figure
2.10 B and 2.11).
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2.2.5

Regulation of polyamine metabolism and combinational tumor inhibition
The above results concluded that HA@F-PaP/siRNA was a suitable siRNA

delivery system which can significantly silence the target gene. We then evaluated the
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ability of HA@F-PaP/siRNA to induce catabolic enzymes SSAT and SMOX. As expected,
treatment with HA@F-PaP/siRNA increased the mRNA expression of both SSAT and
SMOX after 24 h in HCT116 and CT26 (Figure 2.12 A). However, the increased expression
of SMOX was observed after 24 h in KPC8060 cell line and expression of both enzymes
were observed after 48 h (Figure 2.12 B).
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Both BENSpm and siPLK1 can induce apoptosis in cancer cells.[234, 235] So the
ability for nanoparticles to induce apoptosis was analyzed by their nuclear morphology
stained by DAPI. The treatment of HA@F-PaP/siPLK1 bring to more than 40% apoptotic
cells which was significantly more than BENSpm and HA@F-PaP/siNC groups (Figure
2.13 A and 2.14). The pro-apoptotic effect of the nanoparticle was further confirmed by
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cell viability assay. HA@F-PaP/siPLK1 showed significantly higher cell killing as more
than 80% in HCT116 and CT26 cell lines and more than 70% in KPC8060 cell line than
HA@F-PaP/siNC and BENSpm (Figure 2.13 B).
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2.2.6

Biodistribution in orthotopic pancreatic cancer model
The strong anticancer effect in vitro gave us the confidence to study the

biodistribution of the nanoparticles in Pancreatic ductal adenocarcinoma (PDAC) by
orthotopically implanting KPC8060 cells in the tail of the pancreas. Intraperitoneal
delivery can maximize local efficacy by improving the retention time and providing more
interaction opportunities with tumors with limited systemic side effects.[236, 237] To
understand how HA coating affects tumor accumulation after IP injection, Cy3 labelled
polymer and Cy5.5 labelled siRNA were used to quantify the tumor accumulation of
nanoparticles. When the mice were sacrificed 24 h post IP injection, fluorescence of
different organs were measured by IVIS imaging system and semi-quantified by IVIS
software. HA@F-PaP/siRNA showed twice as much fluorescence compared with FPaP/siRNA in both polymer and siRNA indicating the advantages for incorporating the
HA into the nanoparticles (Figure 2.15 A and B). To further investigate the homing effect
of HA, high dose of free HA was injected 1 h prior to the injection of the HA@F-PaP/siRNA.
Fluorescent intensity of HA@F-PaP/siRNA was decreased about 50% in polymer and 70%
in siRNA with the interference of free HA, which demonstrated the HA mediated
targeting accumulation in tumor. We further confirmed the accumulation of the
nanoparticles in tumor by CLSM. Consistent with the IVIS results, HA@F-PaP/siRNA
showed the highest fluorescent intensity compared with other groups (Figure 2.15 C).
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2.2.7

Therapeutic efficacy of HA@F-PaP/siPLK1 in PDAC model
We hypothesized that HA@F-PaP/siPLK1 can achieve enhanced antitumor

efficacy by cooperative effect of F-PaP and siPLK1. Hence, the orthotopic PDAC model
was used to test the therapeutic effect of the nanoparticles. Mice were injected IP with
different formulations every other day after day 21 for a total of 8 doses (Figure 2.16 A).
No overt toxicity was observed as indicated by stable body weight (Figure 2.16 B).
Tumor volume was measured at different time points non-invasively by
ultrasound. On day 35, HA@F-PaP/siPLK1 group showed significantly smaller tumor
volume compared with the other 3 groups (Figure 7C and 7E). Mice were sacrificed and
tumors were collected on day 37. Tumor weight was decreased by 65% with the
combination of polyamine catabolism induction and PLK1 inhibition (Figure 7D). Notably,
HA@F-PaP/siPLK1 had a stronger tumor inhibition compared with free BENSpm
attesting to the advantage of polymeric prodrug that can simultaneously deliver BENSpm
and siPLK1.
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The mice tissues were harvest for HE stains. No tissue toxicity was observed by
examination of H&E-stained slides of major organs compared with untreated group
(Figure 2.17).
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Figure 2.17. HE analysis of different treatment groups. Scale bar=200µm

Additionally, the number of mice with distal metastatic lesions were significantly
less (~50%) in HA@F-PaP/siPLK1 group compared with other groups indicating
substantial antimetastatic effect of the treatment (Figure 2.18 A and D). The PLK1 mRNA
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level was significantly reduced indicating the successful delivery of siPLK1
(Figure 2.18 B). Polyamine catabolism induction was demonstrated by degreased
tumor polyamine concentrations (Figure 2.18 C). Notably, the polyamine
concentration in HA@F-PaP/siPLK1 group reduced by ~75% compared with
untreated

group.

Consistent

with

previous

study,

caspase

3

immunohistochemistry staining indicated the co-operative pro-apoptotic activity
of the HA@F-PaP/siPLK1 nanoparticles (Figure 2.18 E).
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Figure 2.18 Therapeutic evaluation of nanoparticles on PDAC. (A) Number of
mice with metastasis in different organs. (B) RT-PCR analysis of PLK1 mRNA
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64
2.3

Conclusion
In conclusion, the HA coated HF conjugated polyamine prodrug siRNA delivery

system (HA@F-PaP/siPLK1) was developed for highly efficient antitumor effect.
Benefiting from HF in the prodrug and HA coating on the surface, ternary complex
achieved reduced toxicity to the membrane, improved gene silencing effect and selective
targeting to tumor. Moreover, this drug and siRNA delivery system demonstrated
superior apoptosis inducing through combination of inducing polyamine catabolism and
cell cycle arrest in both colorectal cancer and pancreatic cancer. The orthotopic pancreatic
model PDAC was further used to evaluate the antitumor effect and the vicinity of the
peritoneal tumor site in PDAC model makes IP injection a perfect administration method
of the nanoparticles in vivo. The biodistribution study showed selective tumor
accumulation through CD44 targeting effect of HA and, more importantly, HA@FPaP/siPLK1 significantly inhibited the tumor growth compared with BENSpm
monotherapy. The therapeutic effect of nanoparticles on colorectal cancer will be
examined in our follow-up studies. Overall, these results demonstrated that disruption of
polyamine metabolism combined with PLK1 silencing can be a potential combinational
method for cancer therapy and the polymeric polyamine prodrug system can serve as a
novel drug and siRNA delivery system for siPLK1 and other therapeutic nucleic acids in
the field of cancer treatment.
2.4

Materials and methods
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Bis(2-hydroxyethyl)disulfide (BHED), 1,1'-carbonyldiimidazole (CDI), tris(2aminoethyl) amine, heptafluorobutyric anhydride (HFBA), Amberlite IR120 Na+ form,
and glutathione (GSH) were purchased from Sigma-Aldrich (St. Louis, MO).
Dichloromethane (DCM), methanol, and acetonitrile were purchased from Fisher
Scientific (Waltham, MA). Dimethyl sulfoxide-d6 (DMSO-d6), deuterium oxide and
chloroform-d were purchased from Acros Organics (Fair Lawn, NJ). BENSpm was
synthesized as previously described.[238] McCoy’s 5A medium; RPMI1640 medium;
DMEM high glucose medium, Dulbecco’s phosphate buffered saline (PBS), fetal bovine
serum (FBS), penicillin/streptomycin (Pen-Strep) and trypLE express reagent were
purchased from Thermo Fisher Scientific (Waltham, MA).
Polymer synthesis and characterization
First, bis(2-hydroxyethyl) disulfide (BHED) (1.6 g, 10 mmol) was activated
through the addition of CDI (4.6 g, 30 mmol) followed by stirring for 1 h. Then the product
disulfanediylbis(ethane-2,1-diyl) bis(1H-imidazole-1-carboxylate) (compound 2) was
purified by water washing and extract with dichloromethane (DCM) to remove excessive
CDI. The product in DCM layer was dried in sodium sulfate and concentrated under
reduced pressure as white solid (theory as 3.1g, 91%). 1H-NMR (400 MHz, CDCl3) δ 8.21
(s, 2H), 7.46 (s, 2H), 7.12 (s, 2H), 4.71 (t, J=6Hz, 4H), 3.12 (t, J=6Hz, 4H).
N-(2-(bis(2-aminoethyl)amino)ethyl)-2,2,3,3,4,4,4-heptafluorobutanamide (HFTA)
was synthesized by dropwise adding the heptafluorobutyric anhydride dropwise (0.56 g,
1.4 mmol) to tris(2-aminoethyl) amine (2.0 g, 14 mmol) in acetonitrile and then stirred with
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Amberlite® IR120 Na+ form to remove hydrochloride. The product was extracted
with DCM and dried with sodium sulfate before removal under reduced pressure
to obtain the desired product as yellowish paste (0.29 g, 61%). 1H-NMR (400 MHz,
DMSO-d6) δ 3.29-3.23 (m, 2H), 2.68-2.53 (m, 6H), 2.46-2.36 (m, 4H).
Polyamine prodrug was synthesized through step polymerization under
anhydrous conditions. BENspm (85 mg, 0.35 mmol) and compound 2 (0.24 g, 0.70
mmol) was dissolved in DCM and stirred at 40 °C for 18h followed by the addition
of HFTA (60 mg, 0.18 mmol) and tris(2-aminoethyl)amine (17 mg, 0.12 mmol). The
reaction was carried out at room temperature for overnight. Then ethanol was
added, and DCM was under reduced pressure. The product was dialyzed (MWCO
1KDa) against 0.1 mM HCl for one day and then pure DI water for one day before
lyophilization to obtain the white solid (0.13 g, 41%).
Preparation and characterization of nanoparticles
Polymer/siRNA nanoparticles were obtained by mixing equal volume of polymer
and siRNA solutions in 10 mM HEPES buffer (pH = 7.4), followed by the incubation at
room temperature for 30 min. For HA coated nanoparticles, polymer/siRNA nanoparticles
were mixed with equal volume of HA solution and incubated for 20 mins. The
hydrodynamic size and zeta-potential of the nanoparticles were measured by dynamic
light scattering with NanoBrook Omni (Brookhaven instruments, NY). Morphological
study of the nanoparticles was performed under transmission electron microscopy (TEM,
Tecnal G2 Spirit, FEI company, USA) with NanoVAN® negative staining (Nanoprobes,
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USA). The stability of the nanoparticles in serum was assessed by measuring the size at
different time points after the addition of FBS.
The ability of the polymers to condense the siRNA was evaluated in agarose gel
electrophoresis and quantified by SYBR safe. Different w/w ratios of polymer to siRNA
ratio was prepared as mentioned above and loaded into 1.8% agarose gel containing 1X
SYBR safe DNA gel staining (Invitrogen, CA) or put into 96 well plate with 1X SYBR safe
gel staining. The gel was run in 0.5X Tris/Borate/EDTA buffer at 110 V for 15 mins and
visualized with E-gel imager (Life technology, CA) and free RNA was quantified by plate
reader (Molecular Devices, CA) at λex/ λem = 500/555 nm. The degradability of the polymers
was evaluated by incubating the polymers with or without 20 mM GSH at 37 °C for
overnight. Then the ability of the polymers to condense was tested with the method
mentioned above. The degradability of HA@F-PaP/siRNA was confirmed by incubation
of the nanoparticles with or without 20 mM GSH for overnight. The light scattering
intensity of the solutions was quantified by DLS and the morphology of the particles was
studied by TEM as mentioned above.
Cell culture
The HCT116 human colorectal carcinoma cell line was kindly provided by Dr.
Michael Brattain in UNMC cultured in McCoy’s 5A medium supplemented with 10% FBS
and Pen-Strep (100 U/ml, 100 µg/ml). CT26 murine colorectal cancer cell line was
purchased from ATCC (American Type Culture Collection, VA) which was cultured in
RPMI-1640 medium supplemented with 10% FBS and Pen-Strep (100 U/ml, 100 µg/ml).
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KPC8060 derived from KPC PDAC mouse model (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre)
was provided by Dr. Hollingsworth in UNMC and was cultured in high glucose DMEM
supplemented with 10% FBS and Pen-Strep (100 U/ml, 100µg/ml).
Polyamine analysis
Intracellular polyamine concentrations were determined by HPLC following acid
extraction and dansylation of the supernatant, similar to that originally described by
Kabra et al.[227] Standards prepared for HPLC included diaminoheptane (internal
standard), PUT, SPD, and SPM, all of which were purchased from Sigma Chemical Co.
(St. Louis, MO, USA).
Cytotoxicity and LDH release in vitro
Cytotoxicity of the polymers in three cell lines was evaluated by CellTiter-Blue
Cell Viability Assay (Promega, WI). HCT116 and CT26 were plated five thousand per well
and KPC8060 was plated as two thousand per well in the 96-well plate 24 h before
treatments. Different concentrations of polymers were incubated with cells in full cell
culture medium for 24 h. The medium was then removed followed by the addition of the
100 µl full medium and 20 µl CellTiter-Blue reagent in each well. After incubation in 37 °C
for 2 h, the fluorescent intensity [FI] was quantified at λex/ λem = 560/590 nm by plate reader.
The cell viability (%) was calculated by ([FI]treated-[FI]blamk)/([FI]untreated-[FI]blank) ×100.
Polymer concentration that had a 50% viability was considered as IC50 which was
calculated by GraphPad Prism with the dose-response analysis.
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Medium LDH activity of the formulations in three cell lines was evaluated by LDH
cytotoxicity assay kit (Invitrogen, MA). Cells were plated the same concentration as
mentioned above and were allowed 24 h to attach. Then different formulations at 4.8
µg/ml BENSpm equivalent concentration (w/w = 6 polymers 16 µg/ml) and 200 nM siNC
RNA and 10X lysis buffer were incubated with cells in serum free medium for 1 h. 50 µl
of culture supernatant of each well was collected and incubated with 50 µl reaction
mixture for 30mins before addition of 50 µl stop solution. The absorbance [AB] was
measured at 490nm and absorbance at 680 nm was deducted as background. LDH leakage%
was calculated as ([AB]treated-[AB]spontaneous)/([AB]lysis-[AB]spontaneous) ×100.
CD44 expression and cell uptake of the nanoparticles in vitro
Intracellular siRNA concentration was quantified by flow cytometry. Cells were
seeded in 12-well plates 24 h before treatment. Nanoparticles prepared by 100 nM FITC
labeled siRNA (FITC-siRNA) was incubated with cells for 4h in serum free medium. Cells
were washed with PBS and detached for analysis on flow cytometer LSRII (BD Bioscience,
Bedford, MA). Cancer cell surface CD44 expression was verified using fluorescently
labeled monoclonal antibodies CD44-PE clone IM7 (eBioscience, CA) according to the
manufacturer protocol and analyzed by flow cytometry. Subcellular distribution of the
nanoparticles was observed by confocal laser scanning microscopy (CLSM). Cells were
seeded in 8 well chamber (Catalog #: 155409, Fisher Scientific) for 48 h before treatment
for cells to attach. Cells were then treated with Cy5.5 labeled siRNA (Cy5.5-siRNA) in
serum free medium for 4h followed by washing and staining with Hoechst 33342 for livecell imaging in LSM800 laser scanning microscope (Zeiss, Jena, Germany).
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Quantitative real-time polymerase chain reaction (qRT-PCR)
The transfection efficacy of HA@F-PaP/siPLK1 was evaluated by the intracellular
PLK1 mRNA level. HCT116, CT26 and KPC8060 cells were seeded in 6-well plates at a
density of 2×105, 1×105 and 8×104 respectively. Cells were treated with 100 nM siPLK1 or
siNC in serum free medium for 4h followed by the addition of FBS to make the full
medium. After 24 h, total RNA was extracted by TRIzol® (Life technology, CA) according
to the protocol and converted into cDNA with high-capacity reverse transcription kit
(Applied biosystems, CA). Rotor-Gene Q instrument (QIAGEN) was applied to run the
PCR with iTaq Universal SYBR Green Supermix (Bio-Rad laboratories, CA) and GAPDH
primers and PLK1 primers. The relative intracellular mRNA of PLK1 level was expressed
using comparative threshold cycle (Ct) method. Expression of polyamine catabolic
enzyme SSAT and SMOX was also quantified by qRT-PCR through the same process.
Cells were treated with 4.8µg/ml BENSpm, HA@F-PaP/siNC (w/w = 6 200 nM siRNA, FPaP 16 µg/ml) for 24 h. Then the intracellular mRNA level of SSAT and SMOX was
measured with the method mentioned above. The sequences of the primers are listed
below.
Cell cycle arrest assay
HCT116, CT26 and KPC8060 were seeded in 6-well plates at cell concentration as
2×105, 1×105 and 8×104 respectively. After 24 h, cells were treated with different
nanoparticles in serum free medium for 4h followed by the addition of FBS. The cells were
incubated for 24 h and then fixed with 70% ethanol and incubated at 4 °C for 1hr before
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centrifuge and washed twice with PBS. FxCycleTM PI/RNase Staining Solution (Catalog #
F10797, Thermo Fisher Scientific) was added into cells and incubated for 30 mins at room
temperature. Then cells were transferred for flow cytometry analysis.
Apoptosis assay by DAPI staining
Cells were treated with 4.8 µg/ml BENSpm, HA@F-PaP/siNC and HA@FPaP/siPLK1 nanoparticles (16 µg/ml F-PaP equivalent to 4.8 µg/ml BENSpm, 200 nM
siPLK1) for 48 h before stained with 2µg/ml DAPI and observed with EVOS xl
fluorescence microscope (Thermo, US). Condensed or fragmented nuclei was counted as
apoptotic nuclei and the results were expressed as percentage of apoptotic nuclei in the
field.
Cell killing assay
HCT116, CT26 and KPC8060 cells were seeded at 96well plate at density of 5000
cells/well, 2000 cells/well and 1000 cells/well respectively. Cells were allowed to attach for
overnight before treated with different formulations mentioned for 48 h. Then the cell
killing efficacy was quantified by CellTiter-Blue Cell Viability assay as described above.
Orthotopic pancreatic cancer model
Animal study protocols have been approved by the University of Nebraska
Medical Center Institutional Animal Care and Use Committee. Male C57BL/6 mice (7
weeks old) from Charles River Laboratories could acclimate for a week before the
establishment of the orthotopic pancreatic cancer according to the previous method.[236,
237] Briefly, the mice were first anesthetized by IP injection of ketamine/xylazine solution.
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2.5 × 104 KPC8060 cells harvested from culture flask were resuspended in 40 µl 1:1 mixture
of PBS/Matrigel were injected into the tail of the pancreas after an incision (∼1 cm) was
made in the peritoneum at the left side of middle of abdomen region. The abdomen was
closed with 5–0 chromic catgut and soft staples. The staples were removed 12 days after
surgery.
Biodistribution in PDAC model
Orthotopic pancreatic tumor-bearing mice were injected IP with F-PaP/siRNA and
HA@F-PaP/siRNA, which polymer was labelled by Cy3 and siRNA was labelled by Cy5.5.
Each mouse was injected with 2.7 mg/kg BENSpm equivalent polymer and 1.5 mg/kg
siRNA. For HA competitive biodistribution, free HA (10 mg/ml, 200 µl) was injected IP 1
h prior to HA@F-PaP/siRNA injection. Mice were sacrificed 24 h post-injection. Primary
tumors and major organs were harvested for ex vivo imaging using Xenogen IVIS 200
(Ex=535nm, Em=580nm for Cy3 and Ex=675nm, Em=720nm for Cy5.5).
Therapeutic evaluation
Tumor bearing mice were randomly assigned into 4 groups (n=5). Mice were either
untreated or treated with BENSpm (2.7 mg/kg), HA@F-PaP/siNC (2.7 mg/kg BENSpm
equivalent polymer, 1.5 mg/kg siNC), or HA@F-PaP/siPLK1 (2.7 mg/kg BENSpm
equivalent polymer, 1.5 mg/kg siPLK1). The mice were weighed and injected IP every
other day for a total of 8 doses. Tumor size was measured by ultrasound using Vevo 3100
MX550D transducer (40 MHz center frequency, 40 µM axial resolution) in B-mode on day
20, 26 and 35 as previously described.[236] Briefly, mice were put on a heated and
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stationary platform when anesthetized by isoflurane. A motorized transducer adaptor
was used to acquire 3D images. The volume of the tumor was quantified by Vevo lab
software using reconstructed tumor shapes. On day 35, all mice were sacrificed. Primary
tumor was harvested and weighed and metastasis of each organ in each mouse were
recorded.
Histochemical analysis
Tumors and major organs were harvested and fixed with 10% neutral buffered
formalin and stored in 75% ethanol. Major organs were embedded in paraffin and
sectioned for staining with H&E. The apoptosis of the tumor cells was determined by
caspase-3 immunohistochemical staining.
Statistical analysis
All statistical analysis was performed with GraphPad Prism 8. All data are
presented as mean ± SD. Student’s t test and ANOVA were used to analyze difference
between data groups. The significant difference was defined when P<0.05.
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Chapter 3. Folic acid conjugated lipoplex for the delivery of curcumin and siKras as
combinational colorectal cancer treatment

3.1

Introduction

Colorectal cancer is the second most deadly cancer and third most common cancer
in the US.[239] Clinical symptoms are developed late in the course of the diseases, the
early detection of the colorectal cancer is often not achieved.[240, 241] The 5 year survival
rate is less than 15% at the late stage when the cancer has metastasized to distant
organs.[242] Treatment methods of colorectal cancer include surgery, chemotherapy and
radiotherapy with limited efficacy and significant drop in patients’ life quality.[243]
Moreover, few patients are eligible for surgical intervention at late stage and hence,
strategies for safe and effective systemic interventions are needed.[244]
Mutations in Kras account for more than 40% for colorectal cancer associated with
disease progression, metastasis, and survival.[245, 246] RAS genes encode small GTPases
with Kras as the most commonly mutated isoform. Mutations in Kras cause constitutive
activation of multiple downstream pathways leading to cell growth, survival, and
proliferation.[247-249] Additionally, the Kras is also involved in polyamine metabolism.
Mutated Kras activates ODC transcription and translation and inhibit SSAT transcription
implying the increase of cell polyamine concentration for cancer proliferation.[74, 75]
Although Kras is an excellent target for cancer therapy, compounds that direct inhibit
oncogenic Kras was proven to be very challenging due to the lack of druggable pockets
on the surface of Kras.[250, 251] Instead of developing compounds for the undruggable
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gene, RNA interference (RNAi) can be applied as powerful gene silencing tools. Small
interfering RNA (siRNA) can regulate target gene expression through sequence specific
recognition and degradation of mRNA, leading to the decreased expression of target
gene.[252] However, the systemic delivery of siRNA is greatly hampered by limited cell
uptake, fast elimination degradation and clearance of the naked siRNA.[163] To solve this
problem, siRNA can be delivered using positively charged carriers. Currently, cationic
lipids are routinely used for the delivery of nucleic acids and have proved to be effective
siRNA delivery vehicles by forming virus sized complexes with siRNA, termed as
lipoplex.[253, 254] Lipoplex can significantly reduce the dosage of siRNA for effective
gene silencing by enhancing their siRNA stability and improving cell uptake.[255]
Curcumin is a natural yellow phenolic compound extracted from turmeric
(Curcumin longa) with many pharmacological activities including anti-cancer. For
centuries, curcumin has been used as spice and dietary supplements. In recent study, the
anti-cancer activity of curcumin has been extensively investigated and curcumin showed
both prevention and treatment effects for varieties of cancers including colorectal
cancer.[256, 257] The mechanisms of the anti-cancer activity are involved with many key
transcription factors, protein kinases, growth factors and pro-inflammatory factors. [258]
Surprisingly, curcumin was also reported as polyamine metabolism regulator in
gastrointestinal cancer, breast cancer and colorectal cancer.[259-262] By upregulating the
polyamine catabolic rate limiting enzymes (SSAT and SMOX) and down regulating the
synthetic rate limiting enzymes (ODC and AdoMetDC), the cancer cell polyamine
concentration was decreased, which functions similarly as BENSpm. Although clinical
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study suggested that curcumin was well tolerated at 12 g/kg by oral administration, the
bioavailability of curcumin is too low to achieve therapeutic effect due to low aqueous
solubility.[256, 263-265] The obvious approach to improve the biopharmaceutical
properties of curcumin is to improve its aqueous solubility. Many studies have
demonstrated that application of nanocarriers can improve the curcumin’s aqueous
solubility and bioavailability such as polymeric micelles and liposomes.[266, 267]
In this study, we report the development of curcumin and siKras loaded cationic
lipoplex as drug/siRNA combinational therapy against colorectal cancer. Folic acid was
also conjugated into the lipoplex to achieved improved siRNA delivery efficacy.[268, 269]
We hypothesize folic acid conjugated lipoplex can efficiently deliver both curcumin and
siKras to achieve enhanced anticancer efficacy through anti-metastasis and co-operative
apoptosis induction.
3.2

Results and discussion

3.2.1

Preparation of and characterization of lipoplex
Folate receptor that is overexpressed in cancer cells can be exploited as a

straightforward approach for targeting, which resulted in improved cell uptake and
tumor accumulation.[270-272] Thus, we have synthesized folic acid (FA) conjugated
PEGylated cholesterol to incorporated into the lipoplex (Figure 3.1). According to the 1HNMR, in FA-PEG-Chol the molar ratio of FA: PEG is 0.4:1.
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Figure 3.1 Synthesis scheme and characterization of FA-PEG-Chol. (A) Synthesis
1

scheme of FA-PEG-Chol. (B) H-NMR characterization of the FA-PEG-Chol.

Then the curcumin loaded liposome was prepared by the traditional thin film
method with the molar ratio as DDAB: DOPE: cholesterol: sodium cholate: mPEG-DSPE/
FA-DSPE-Chol = 45: 30: 10: 13: 2 or 45: 30: 10: 10: 5. Passive liposome with 2% PEG
(2PLP), folate receptor targeted liposome with 2% PEG or 5% PEG (2FLP and 5FLP) and
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their curcumin loaded liposome (2PLPC, 2FLPC and 5FLPC) were characterized (table
3.1).

Table 3.1 Summary of different liposomes.

The lipoplex was prepared by mixing different liposomes with siRNA at various
N/P ratio. Agarose gel retardation was used for characterization of the encapsulation
efficiency of liposome entrapped siRNA. All the liposomes can efficiently entrap the
siRNA at N/P = 4 (Figure 3.2). The encapsulation of curcumin did not obviously impact
the siRNA condensation. Notably, the curcumin loaded liposomes had strong signal at
the loading area of the gel shown in lane B (curcumin loaded liposome only) due to the
fluorescence nature of curcumin.[273]
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Figure 3.2 Gel retardation assay of different lipoplexes at various N/P ratio.

DLS analysis showed particles sizes ranging from 100 nm to 300 nm at different
N/P ratio (Figure 3.3 A). At N/P = 5, the sizes of 2%FLP and 2%FLPC was around 400 nm,
but with the increase of the N/P ratio, the sizes reduced to around 200 nm at N/P = 10.
Meanwhile, all the formulations had positive zeta-potential where lipoplexes contains 2%
PEG had higher zeta-potential compared with 5% PEG lipoplexes probably due to the
shielding effect of the PEG (Figure 3.3 B).[274, 275]
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We also studied the stability of the lipoplexes under different conditions. For
systemic administration, the blood contains anions that can bind with the cationic
lipoplexes leading to increased size. Additionally, blood heparin can compete with siRNA
for cations, releasing the condensed siRNA. We first evaluated the colloidal stability of
the lipoplexes in PBS by measuring the size of lipoplexes at different time points. All the
lipoplexes demonstrated excellent stability in PBS with size increasement less than 5%
(Figure 3.4 A). Then the heparin integration stability was assessed using gel retardation
assay where different concentrations of heparin were used to destabilize the lipoplexes.
As mentioned before, the fluorescent nature of the curcumin can affect the quantification
of this study. Thus, lipoplexes without curcumin was used. Additionally, increase of N/P
ratio can increase the stability of the lipoplexes against heparin since the formulation will
have more free cationic lipids to buffer the effect of heparin. Hence, only N/P = 10 was
used in this study. The results showed no obvious difference between different lipoplexes
that siRNA in all of them were release at 80 µg/ml of heparin (Figure 3.4 B and C).
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3.2.2

Anticancer effect of curcumin loaded liposome

Since curcumin has been reported as a potent anticancer agent, we want to validate
that the curcumin loaded liposomes have similar therapeutic effects as free curcumin.
Human colorectal cancer cell line HCT116 was used in the study. Cell viability assay by
CellTiter Blue (CTB) of different formulations were evaluated after 24 h treatment. The
free cationic liposome showed minimal toxicity to cancer cells indicating the safety of the
formulation. However, when the curcumin was loaded into the liposome, cell viability
dropped to less than 50% at curcumin concentration as 8 µg/ml. Similar results were seen
in both 2FLPC and 5FLPC (Figure 3.5 A and B). Then the mechanism of anticancer was
demonstrated by RT-qPCR. When the cells were treated with different formulation for 24
h, the key polyamine catabolism enzyme SSAT was upregulated indicating the linkage of
the curcumin to polyamine metabolism. Additionally, curcumin is known as NF-κB and
STAT3 inhibitor. Inhibition of NF-κB can reduce the downstream apoptosis suppressor
proteins like BCL2. Thus, both BCL2 and STAT3 expression were down regulated
implying the induced apoptosis after the treatment (Figure 3.5 C). The anti-metastasis
effect of curcumin was also evaluated due to the interaction of multiple pathways
including STAT3.[276] Cells were treated with different formulation before the migration
assay. Induced by 10% FBS, PBS, 2FLP and 5FLP treated groups had high amounts of
migrated cells (Figure 3.5 D and E). Although at 4 µg/ml, both 2FLPC and 5FLPC showed
about 80% of viability after 24 h, there were significantly less migrated cells compared
with the groups without curcumin. Additionally, the anti-migration effects were similar
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amount 2FLPC, 5FLPC and free curcumin. Based on those data, we can conclude that
curcumin when loaded into the liposome had similar anticancer effects and mechanism
as free curcumin.
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Figure 3.5 Effects of FLPC in HCT116 cell line. (A) and (B) Cell viability assay of
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as mean ± SD (n = 3). **P<0.01, ***P<0.001, P<0.0001.
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3.2.3

Enhanced siRNA uptake of 2FLPC

Folate receptor is overexpressed in HCT116 cell line and folic acid conjugated
nanoparticles was reported to be readily uptake mediated by the interactions between
folic acid and folate receptors.[268, 277] Thus, we used flow cytometry and fluorescent
labeled siRNA to quantify the mean fluorescent intensity (MFI) of different lipoplexes at
different N/P = ratio. After treat the cells for 4 h, 2FLP/siRNA at w/w = 10 showed
significantly higher MFI compared with 2PLP/siRNA indicating the advantage of
incorporating the folic acid into the lipoplexes (Figure 3.6 A). However, with the
increment of FA content, the PEG content started to be the dominate role in cell uptake
evident in reduced MFI in 5FLP. Furthermore, in 2FLP group, N/P = 5 had about 60% MFI
compared with N/P = 10 but N/P = 20 was only 10% more than N/P = 10. Considering that
increasing N/P ratio will reduce the siRNA wt%, N/P = 10 was selected for further study.
We further confirmed the results of flow cytometry by confocal microscopy. Three
lipoplexes at N/P = 10 was used and more cy5.5 labeled siRNA (red) was observed in 2FLP
group (Figure 3.6 B).
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Figure 3.6 Cell uptake of the lipoplexes in HCT116 cell line. (A) Flow cytometry
analysis of 4 h uptake in HCT116 cells (100 nM FITC-siRNA). (B) Confocal microscopy
observation of HCT116 cells with treatment (N/P = 10) for 4 h containing 100 nM cy5.5
labeled siRNA (red). Nuclei stained with DAPI (blue). Scale bar = 20 µm. ****P<0.0001.
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3.2.4

Combinational cancer inhibition of 2FLPC/siKras
Having confirmed the successful curcumin and siRNA delivery into the cells, the

combinational effects of curcumin and siKras was evaluated. HCT116 cells were treated
with different formulations and the viability of each day was monitored by CTB assay.
FLPC/siKras showed excellent anti-proliferative effect with about 50% viability on day 3,
which was significantly stronger than both FLPC/siNC and FLP/siKras indicating the
cooperative anticancer effect (Figure 3.7 A and B). Additionally, annexin V-Pi apoptosis
assay was used to quantify the apoptotic cells after treated with FLPC/siKras. Consistent
with previous results, FLPC/siKras demonstrated about 50% apoptotic cells with
significant different compared with other groups (Figure 3.7 C).
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Figure 3.7 Combinational effect of 2FLPC/siKras HCT116 cell line. (A) Cell

growth curve after treatment of different formulations (N/P = 10, 4.5 µg/ml
curcumin, 150 nM siRNA). (B) Cell viability assay after treatment with different
formulations for 72 h. (C) Cells were treated with different formulations for 24 h
(N/P = 10, 6.0 µg/ml curcumin, 200 nM siRNA). Flow cytometry analysis of
apoptosis was performed by Annexin V-FITC/PI staining. ***P<0.001, ****P<0.0001.
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3.3

Conclusion
In conclusion, we have successfully developed curcumin and siKras loaded and

folic acid conjugated lipoplex (2FLPC/siKras) for colorectal cancer. Curcumin loaded
liposome demonstrated similar anti-proliferation and anti-migration effects as free
curcumin. Benefiting from the folic acid, the 2FLPC/siRNA had enhanced siRNA delivery
efficacy. Finally, the combination of curcumin and siKras demonstrated superior cancer
proliferation inhibition and apoptosis inducing effect.
3.4

Materials and methods
Curcumin, cholesteryl chloroformate, cholesterol, diisopropylethylamine, sodium

cholate, N-(3-Dimethylaminopropyl)-N ′ -ethylcarbodiimide hydrochloride (EDC), (Nhydroxysuccinimide) (NHS) and were purchased from Sigma-Aldrich (St. Louis, MO).
Diaminopolyethylene glycol was purchased from Creative PEGWork (Chapel Hill, NC).
Dimethyldioctadecylammonium
phosphoethanolamine

(DOPE),

bromide

(DDAB),

1,2-dioleoyl-sn-glycero-3-

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[methoxy(polyethylene glycol)-2000] were purchased from Avanti polar lipids (Alabaster,
AL). McCoy’s 5A medium, Dulbecco’s phosphate buffered saline (PBS), fetal bovine
serum (FBS), penicillin/streptomycin (Pen-Strep) and trypLE express reagent were
purchased from Thermo Fisher Scientific (Waltham, MA). Dichloromethane (DCM),
acetonitrile and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific
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(Waltham, MA). Dimethyl sulfoxide-d6 (DMSO-d6) was purchased from Acros Organics
(Fair Lawn, NJ).
Synthesis and characterization of FA-PEG-Chol
Diaminopolyethylene glycol (200 mg, 0.1 mmol) and diisopropylethylamine (56 µl,
0.3 mmol) was dissolved in DCM and cholesteryl chloroformate (49 mg, 0.11 mmol)
dissolved in DCM was added dropwise into diaminopolyethylene glycol solution. The
reaction was proceeded for overnight before the removal of DCM under reduced pressure.
Then folic acid (88 mg, 0.19 mmol), EDC HCl (58 mg, 0.30 mmol), and NHS (35 mg, 0.30
mmol) dissolved in DMSO was directly added into the reaction mass for overnight
reaction. The crude product was dialyzed against water to remove the impurities and
lyophilized to yield a yellow solid (232 mg, 83%). FA-PEG-Chol was characterized by 1HNMR (400MHz, DMSO-d6).
Preparation of curcumin and siRNA loaded lipoplex
Curcumin loaded cationic liposome was first prepared by traditional thin film
hydration method. Briefly, DDAB, DOPE, cholesterol, sodium cholate and mPEGDSPE/FA-PEG-Chol (molar ratio= 45: 30: 10: 13: 2 or 45: 30: 10: 10: 5) were dissolved in
methanol at 10 mg/ml (with 1 mg/ml curcumin for PLPC or FLPC). The solvent was
removed by rotary evaporator and further dried under vacuum overnight to remove
traces of organic solvent. The dried lipids were hydrated with HBG buffer (20 mM HEPES
buffer with 5% glucose) to make a lipid concentration as 5 mg/ml. The liposome
suspension was centrifuged (1000g, 5min) to remove free curcumin. The supernatant was
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extruded through 1 µm and 0.4 µm pore size polycarbonate membrane for 10 cycles with
miniextruder (Avanti polar lipids, AL) to form the liposome. The loaded curcumin was
determined by HPLC (Agilent, CA) at acetonitril/water (70:30) 1 ml/min with UV detector
(425 nm). The total weight of the liposome was measured after freeze drying the liposome.
The drug loading efficacy was determined using the following equation:

𝐷𝐿% =

Weight of loaded curcumin
× 100%
Weight of total liposome

The cationic lipoplex was prepared by mixing cationic liposome with siRNA at
different N/P ratio in HBG buffer and incubated under room temperature for 30 mins
before further use.
Characterization of curcumin loaded lipoplex
The hydrodynamic size and zeta-potential of different formulations were
measured by dynamic light scattering with NanoBrook Omni (Brookhaven instruments,
NY). PBS colloidal stability was assessed by incubating the lipoplexes with PBS at 37 °C
and the size was monitored at different time point.
Gel retardation assay was used to evaluate the ability of the liposome to condense
siRNA and quantified by SYBR safe. Different N/P ratios of lipids to siRNA was prepared
as mentioned above and loaded into 1.8% agarose gel containing 1X SYBR safe DNA gel
staining (Invitrogen, CA) or put into 96 well plate with 1X SYBR safe gel staining. The gel
was run in 0.5X Tris/Borate/EDTA buffer at 110 V for 15 mins and visualized with E-gel
imager (Life technology, CA) and free RNA was quantified by plate reader (Molecular
Devices, CA) at λex/ λem = 500/555 nm. The heparin stability was confirmed by incubation
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of lipoplexes with different concentrations of heparin at 37 °C for 30 min. The free RNA
was quantified through the method mentioned above.
Cell culture
The HCT116 human colorectal carcinoma cell line was kindly provided by Dr.
Amar Singh in UNMC cultured in McCoy’s 5A medium supplemented with 10% FBS and
Pen-Strep (100 U/ml, 100 µg/ml).
Cytotoxicity assay
Cytotoxicity of the different formulations was evaluated by CellTiter-Blue (CTB)
Cell Viability Assay (Promega, WI). HCT116 were plated at 5000 cells/well in 96 well plate
24 h before treatments. Different concentrations of curcumin, lipids and liposomes were
incubated with cells in full cell culture medium for 24 h. The medium was then removed
followed by the addition of the 100 µl full medium and 20 µl CellTiter-Blue reagent in
each well. After incubation in 37 °C for 2 h, the fluorescent intensity [FI] was quantified at
λex/ λem = 560/590 nm by plate reader. The cell viability (%) was calculated by
([FI]treated-[FI]blamk)/ ([FI]untreated-[FI]blank) ×100.
Cancer cell proliferation inhibition was evaluated by CTB assay. HCT116 cells
were plated at 1000 cells/well in 96 well plate 24 h before treatment. Before treatment, CTB
assay was performed, and fluorescence intensity was regarded as 100%. Different
formulations (4.5 µg/ml curcumin and 150 nM siRNA) were prepared and treated to cells
in serum free medium for 4 h followed by the FBS addition. Instead of replacing with fresh
medium, direct FBS addition gave cells time to attach and avoided the living cells to be
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removed from the plate. Then the cells were incubated for 24 h before change to the fresh
medium. Then at different time, the viability of the cells was evaluated through the
method mentioned above.
Quantitative Real-Time polymerase Chain Reaction (qRT-PCR)
HCT116 cells were seeded onto 6 well plate at 4 × 105 cells per well for 24 h
incubation and treated with different formulations at curcumin concentration 4 µg/ml.
After 24 h, total RNA was extracted from cultured cells using TRIzol® (Life technology,
CA) according to the manufacturer protocol and converted into cDNA with high-capacity
reverse transcription kit (Applied biosystems, CA). Rotor-Gene Q instrument (QIAGEN)
was applied to run the PCR with iTaq Universal SYBR Green Supermix (Bio-Rad
laboratories, CA). The relative intracellular mRNA to GAPDH of SSAT, Bcl-2 and STAT3
level was expressed using comparative threshold cycle (Ct) method.
Migration assay
HCT116 cells were harvested and resuspended in serum free medium. Cells were
pretreated with different formulations for 30 min and added into cell culture inserts (8.0
µm pores, BD Biosciences) (5 × 104/ insert). The lower transwell chamber was filled with
600 µl 10 % FBS cell culture medium. After 24 h migration, the cells on the top chamber
were removed by cotton swabs. The migrated cells were fixed with methanol and stained
with 0.5% Crystal Violet. The images were acquired by EVOS xl microscope and results
were expressed as number of migrated cells per view.
Cell uptake of lipoplex
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Flow cytometry was applied to quantify the intracellular siRNA content. HCT116
cells (1 × 105 cells /well) were seeded into 12 well plates 24 h before treatment. Lipoplexes
at different N/P ratio prepared by 100 nM FITC labeled siRNA (FITC-siRNA) was
incubated with cells in serum free medium for 4 h. Cells were washed with PBS and
detached for analysis on flow cytometer LSRII (BD Bioscience, Bedford, MA). Cell uptake
of the lipoplex was also observed by confocal laser scanning microscopy (CLSM). Cells
were seeded in 8 well chamber (Catalog #: 155409, Fisher Scientific) for 24 h before
treatment. Cells were then treated with Cy5.5 labeled siRNA (Cy5.5-siRNA) (N/P = 10) in
serum free medium for 4 h followed by staining with Hoechst 33342 for live-cell imaging
in LSM800 laser scanning microscope (Zeiss, Jena, Germany).
Apoptosis assay
HCT116 cells were plated into 6 well plate (3 × 105 / well) 24 h before treatment.
Formulations (6 µg/ml curcumin and 200 nM siRNA) were incubated with cells for 24 h
and harvested for processing. Annexin V-FITC/PI apoptosis detection kit (BioLegend, CA)
was used to analyze the apoptosis using flow cytometry according to the manufacturer
protocol.
Statistical analysis
All statistical analysis was performed with GraphPad Prism 8. All data are
presented as mean ± SD. Student’s t test and ANOVA were used to analyze difference
between data groups. The significant difference was defined when P<0.05.
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Chapter 4. Synthesis of reducible norspermine polymers

4.1

Introduction

BENSpm was reported as one of the most potent polyamine analogues with
excellent anticancer efficacy in multiple preclinical models. However, in clinical trials, the
therapeutic effects of the BENSpm was limited due to short half-life.[108] In this study,
we proposed using reducible polymeric prodrug to increase the therapeutic efficacy of
BENSpm. We previously reported the application of step-growth polymerization for the
synthesis BENSpm prodrug using immolative disulfide linker.[222, 223] Although the
polymer was successfully synthesized, further modification of the polymer was difficult.
In this study, we tried to synthesize the prodrug BENSpm monomer that can be used for
reversible addition-fragmentation chain transfer (RAFT) polymerization. We used
norspermine as substitute to develop the synthetic strategy.
The materials and overall characterization methods are first described. The
methods of synthesizing the small molecules and polymers would be described closely
followed by the nuclear magnetic resonance (NMR) of the product. The gel permeation
chromatography (GPC) data and other characterization would also be demonstrated.
4.2

Materials

Norspermine, trifluoroethyl acetate, Di-tert-butyl decarbonate (Boc2O), lithium
hydroxide (LiOH), sodium sulfate, carbonyldiimidazole (CDI), triisopropylsilyl (TIPS)
chloride, triethylamine (TEA) and 4-dimethylaminopyridine (DMAP), 2-bishydroxyethyl
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disulfide (BHED), methacryloyl chloride, 2-Hydroxypropyl methacrylamide (HPMA),
1M

HCl

in

ethyl

acetate,

poly(ethylene

glycol)methyl

ether

4-cyano-4-

(dodecylsulfanylthiocarbonyl) sulfanylpentanoate (dodecyl-trithiocarbonate-cyano PEG),
azobisisobutyronitrile (AIBN), 4-Toluenesulfonyl chloride (TsCl), Sodium azide, copper
sulfate pentahydrate, sodium ascorbate, allylpropargylamine hydrochloric salt,
methacrylic

acid

(MAA),

propargylamine,

1-Ethyl-3-(3-dimethylaminopropyl)

carbodiimide (EDC), 4,4′-Azobis(4-cyanopentanoic acid) (ACVA) were purchased from
Sigma Aldrich (St. Louis, MO). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), penicillin-streptomycin, fetal bovine serum (FBS) and tripLE were purchased
from Thermal Fisher Scientific (Waltham, MA). Tetrahydrofuran (THF), dichloromethane
(DCM), methanol, ethyl acetate, hexane, dimethyl sulfoxide (DMSO), dimethylformamide
(DMF) and chloroform were purchased from Fisher Scientific (Waltham, MA).
NMR was obtained through Bruker Avance III HD 400 MHz and 500 MHz and the
data were processed with Topspin 4.07 (Bruker). The molecular weight of the cationic
polymers was measured by gel permeation chromatography (GPC) with 0.1 M sodium
acetate buffer (pH 5.0) as eluent. The GPC was using Agilent 1260 Infinity LC system
equipped with a miniDAWN TREOS multi-angle light scattering (MALS) detector and an
Optilab T-rEX refractive index detector from Wyatt Technology (Santa Barbara, CA). The
column TSKgel G5000PWXL-CP (Tosoh Bioscience LLC, King of Prussia, PA) was
running at 0.5 mL/min flow rate with constant temperature as 25 °C. Results were
analyzed using Astra 6.1 software from Wyatt Technology.
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4.3

Methods and results

4.3.1

Synthesis of triboc-norspermine

We first synthesized triboc-norspermine since this compound would be frequently
used in the future study. The synthesis route was described at Scheme 4.1.

Scheme 4.1 Synthesis of triboc-norspermine.

Norspermine (2.0 g, 11 mmol) was dissolved in 10ml methanol and trifluoroethyl
acetate was added dropwise into norspermine solution at -80oC under vigorous stirring
for one hour. Then Boc2O (17 g, 80 mmol) was dissolved in 10ml methanol and added into
the reaction mass. The reaction was stirred overnight before hydrolysis. The reaction mass
was then concentrated under reduced pressure through rotary evaporation and 10 ml
THF was added. LiOH (2.5 g, 0.10 mol) was dissolved in 20 ml water and was added into
the reaction mass and stirred overnight. The final compound triboc-norspermine was
purified first by extraction with DCM and washed with brine for 3 times before dried with
anhydrous sodium sulfate. After the DCM was removed, flash silica gel chromatography
was used to purify the product. The recommended elute solvent system start from 30%
ethyl acetate in hexane to 100% ethyl acetate. Then switch the elute system to
methanol/DCM system. The product was eluted at approximately 10% methanol in DCM
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as white paste (2.0 g, 34%) (Figure 4.1). 1H NMR (500MHz, CDCl3) δ 3.35-3.05 (m, 10H),
2.89 (bs, 2H), 1.85-1.71 (m, 6H), 1.50-1.41 (m, 27H).

Figure 4.1 1H NMR of triboc-norpsermine in CDCl3.
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4.3.2

Synthesis of polymeric norpsermine prodrug monomer 6

We first attempted to synthesize the monomer 6 that could be polymerized
through RAFT polymerization. The monomer 6 was using norpsermine instead of
BENSpm due to the availability of BENSpm and we believe the chemistry that worked for
norspermine should also work for BENSpm. Thus, norspermine was selected for the
reaction. Due to the possibility of Michael Addition on the highly reactive methacrylate,
the primary amine was incorporated first, then the double bond was introduced into the
monomer (Scheme 4.2).

Scheme 4.2 Synthesis of norspermine prodrug monomer 6.
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4.3.2.1 Synthesis of compound 2

One side of the hydroxyl group was first protected due to the high reactivity of
carbonyldiimidazole (CDI). Triisopropylsilyl (TIPS) chloride (2.5 g, 13 mmol),
triethylamine (2.2 ml, 16 mmol) and 4-dimethylaminopyridine (DMAP) (0.24 g, 2.0 mmol)
were dissolved in 40 ml DCM and loaded into dropping funnel. The TIPS chloride
solution was slowly dropped into Compound 1 (BHED) (2.0 g, 13 mmol) in 10 mL DCM
under vigorous stirring and ice bath. After overnight stirring, the reaction mass was
purified by water washing for 3 times and the raw product was concentrated under
reduced pressure followed by a flash silica gel chromatography to obtain compound 2 (1.9
g, 46%) (Figure 4.2). 1H NMR (400MHz, CDCl3) δ 3.95 (t, J=6.4Hz, 2H), 3.90 (t, J=6.0Hz, 2H),
2.87 (m, 4H), 1.08 (m, 21H).

Figure 4.2 1H NMR of compound 2 in CDCl3.
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4.3.2.2 Synthesis of compound 3

The remaining hydroxyl group was activated by CDI. Compound 2 (0.50 g, 1.6
mmol) was dissolved in 5 ml DCM. CDI (0.79 g, 4.8 mmol) was dispersed in 5 mL DCM
and added slowly into compound 2 under ice bath and stirring. The reaction was kept in
ice bath for 1 h. Then water was directly added into the reaction under vigorous stirred
for 5 min to quench the excessive CDI. The product was extracted by DCM and dried
under vacuum for overnight to remove traces of water.
4.3.2.3 Synthesis of compound 4

The activated hydroxyl group was then reacted with the primary amine in tribocnorspermine. Compound 3 (0.63 mg, 1.6 mmol) and triboc-norpsermine (0.92 mg, 2.0
mmol) were dissolved in 5 ml DMF and stirred at 45 °C in oil bath for overnight. Then
excessive DCM was added, and the reaction was washed with water. The DCM layer was
separated and removed under reduced pressure. Raw product was further purified by
flash silica gel chromatography and was eluted at approximately 30% ethyl acetate in
hexane as compound 4 (1.0 g, 79%) (Figure 4.3). 1H NMR (400MHz, CDCl3) δ 4.32 (t, 6.4Hz,
2H), 3.94 (t, J=6.8Hz, 2H), 3.32-3.07 (bs, 12H), 2.95-2.85 (m, 4H), 1.80-1.62 (bs, 6H), 1.51-1.42
(m, 27H), 1.17-1.04 (m, 21H). Other 3 peaks were from ethyl acetate (the NMR spectrum
was obtained before the drying and yield calculation).
4.3.2.4 Synthesis of monomer 6
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Figure 4.3 1H NMR of compound 4 in CDCl3.
The silyl group was removed by tetrabutylammonium fluoride (TBAF).
Compound 4 (0.36 g, 0.45 mmol) was mixed with 1 M TBAF tetrahydrofuran (THF)
solution (4.5 ml, 4.5 mmol) and stir for overnight. The raw product was purified by water
washing and extraction with DCM. After dried with sodium sulfate, DCM was removed
under reduced pressure to obtain compound 5. Then the double bond was directly
introduced into compound 5 without further purification.
Compound 5 (0.13 g, 0.20 mmol) and triethylamine (88 µl, 0.63 mmol) were
dissolved in 3 ml DCM. Methacrylol chloride (62 µl, 0.63 mmol) was dissolved in 5 ml
DCM and slowly added into compound 5 in ice bath. The reaction was allowed to stir for
overnight. Resulting product was concentrated under reduced pressure and purified by
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flash silica gel chromatography at about 20% ethyl acetate in hexane. The monomer 6 had
a yield of 41% (Figure 4.4). 1H NMR (400MHz, CDCl3) δ 6.12 (s, 1H), 5.58 (s, 1H), 4.40 (t,
J=4.0Hz, 2H), 4.29 (t, J=4.0Hz, 2H), 3.34-3.03 (bs, 12H), 3.02-2.86 (m, 4H), 1.94 (s, 3H), 1.801.53 (bs, 6H), 1.52-1.33 (m, 27H). Peaks δ 4.11, 2.03, 1.25 belong to residual ethyl acetate
solvent (the NMR spectrum was obtained prior to the drying and yield calculation).

Figure 4.4 1H NMR of monomer 6 in CDCl3.
The double bond peaks at 6.12 ppm and 5.58 ppm and methyl group at 1.94 ppm indicated
the success of the reaction and the successful synthesis of monomer 6 for further
polymerization. The deprotection of monomer 6 was planned after the polymerization
due to the radical scavenging nature of the free amines and potential Michael addition on
the double bonds.
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4.3.3

Synthesis of polymeric norspermine prodrug 8

Reverse addition fragmentation chain transfer polymerization (RAFT) was
selected for the polymerization due to its low molecular weight dispersity. The synthesis
scheme is described in Scheme 4.3. The monomer 6 and 2-Hydroxypropyl
methacrylamide (HPMA) were dissolved in dimethylformamide (DMF) and put into the
ampule. Then the dodecyl-trithiocarbonate-cyano PEG as chain transfer agent (CTA) and
azobisisobutyronitrile (AIBN) as initiator was added into the ampule to make the reaction
mass concentration as 70 mg/ml. The ampule was purged with nitrogen for 30 min and
sealed. The reaction was stirred for 2 days at 65 °C and purified by dialysis in DMF for
one day and in methanol for 4 h. Then the solvent was evaporated and 1M HCl in ethyl
acetate was added and stirred for one day to remove the Boc group. The final prodrug 8
was purified by extensive dialysis (MWCO = 3.5kDa) in water followed by lyophilization.

Scheme 4.3 Synthesis of polymeric norspermine prodrug 8.
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However, due to the hydrolysis of the ester bond in the polymers, there were
barely any product after lyophilization. Thus, a more stable monomer was later developed
to solve this problem.
4.3.4

Synthesis of norspermine monomer 13

To synthesize the monomer that could resist the acid condition when deprotecting
the Boc group, a new scheme was designed that switch the labile ester bond as carbon
nitrogen bond (Scheme 4.4). Because there were two hydroxyl groups and the link
between the norspermine and the disulfide linker must be either ester bond, carbamate
bond or carbonate bond, we first attempted to convert only one side of the hydroxyl group
to an alkene bond by using allyl bromide at the condition of sodium hydride. However,
the reaction turned out to be unsuccessful probably due to the break of the disulfide bond
which then reacted with the bromide group. Thus, we decided to convert one side of the
hydroxyl group to azide group first. Then through click chemistry, the double bond was
introduced.
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Scheme 4.4 Synthesis of norspermine monomer 13.
4.3.4.1 Synthesis of compound 9

Mono-tosylated BHED could be obtained by dropping the tosyl chloride. However,
there would be mono and di-substituted products which would reduce the yield of this
reaction. 4-Toluenesulfonyl chloride (TsCl) (2.0 g, 11 mmol), triethylamine (TEA) (1.5 ml,
11 mmol) and DMAP (0.20 g, 1.6 mmol) were dissolved in 50 ml DCM and dropped into
BHED (5.0 g, 33 mmol) under ice bath and vigorous stirring. The reaction was stirred for
overnight then washed with water. DCM were removed under reduced pressure and
methanol was added to dissolve the raw product. Sodium azide (14 g, 0.22 mol) was
dissolved in DI water and mixed with the raw product. The reaction was taken at 60 °C
for overnight. Excessive sodium azide was removed by water wash and compound 9
(liquid, 31%) was purified by silica chromatography which eluted at 40% ethyl acetate in
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hexane (Figure 4.5). 1H NMR (400MHz, CDCl3) δ 3.92 (t, J=6.0Hz, 2H), 3.63 (t, J=6.8Hz, 2H),
2.90 (m, 4H), 1.97 (bs, 1H).

Figure 4.5 1H NMR of compound 9 in CDCl3.
4.3.4.2 Synthesis of compound 10

Click chemistry was applied to introduce the alkene bond. Compound 9 (0.10 g,
0.56 mmol) and allylpropargylamine hydrochloric salt (82 mg, 0.63 mmol) were first
dissolved in methanol and DI water respectively. Then copper sulfate pentahydrate (16
mg, 64 µmol) and sodium ascorbate (NaAs) (40 mg, 0.20 mmol) were added as catalyst.
The click chemistry was conducted at 40 °C for overnight. Then Boc2O (0.27 g, 1.2 mmol)
and triethylamine (0.17 ml, 1.2 mmol) in ethanol was added to protect the amine group
for overnight. The raw product was first extracted with DCM and washed with water to
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remove all the salt. Then the solvent was dried at anhydrous sodium sulfate before
removed under reduced pressure. Flash silica gel chromatography was used to obtain
compound 10 (0.18 g, 88%) at 30% ethyl acetate in hexane (Figure 4.6). 1H NMR (400MHz,
CDCl3) δ 7.70-7.43 (bs, 1H), 5.76 (m, 1H), 5.14 (m, 2H), 4.67 (m, 2H), 4.46 (s, 2H), 3.87 (m,
4H), 3.16 (t, J=6.4Hz, 4H), 2.88 (t, 6.0Hz, 2H), 1.45 (s, 9H). The other three peaks were from
solvent ethyl acetate (The NMR spectrum was obtained prior to the drying and yield
calculation).

Figure 4.6 1H NMR of compound 10 in CDCl3.
The new peak at δ 7.63 ppm showed the success of the click reaction. The Boc
group was introduced into the molecule since the next step was CDI activation. Here,
amine groups were introduced after the double bond because allyl group was less reactive
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than the methacrylate due to the absence of the carboxyl group. However, this reaction
could also be done by introducing amines first then click on the allyl propargylamine.
4.3.4.3 Synthesis of compound 12

The CDI coupling reaction from the remaining hydroxyl group with tribocnorspermine was completed through procedure as mentioned before. Compound 11 was
coupled with triboc norspermine in DCM instead of DMF since DCM was easier to
remove. Compound 11 was dried overnight under vacuum to remove excessive moisture.
Compound 11 was then coupled with triboc-norpsermine. Compound 12 was
purified by flash silica chromatography at approximately 10% methanol in DCM.

4.3.4.4 Synthesis of monomer 13
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Compound 12 (0.12 g, 0.14 mmol) was dissolved 1ml 1 M HCl in ethyl acetate and
stirred overnight to completely remove the Boc group. Then the solvent and side products
were removed by reduced pressure and monomer 13 was obtained as white solid (74 mg,
80%) demonstrating the stability of carbon nitro bond (Figure 4.7). 1H NMR (400 MHz,
D2O) δ 8.17 (s, 1H), 5.84-5.70 (m, 1H), 5.35 (m, 2H), 4.26 (s, 2H), 4.13 (m, 2H), 3.56 (m, 2H),
3.66 (m, 2H), 3.25-2.74 (m, 16H), 2.07 (m, 4H), 1.85 (m, 2H).

Figure 4.7 1H NMR of monomer 13 in D2O.
4.3.5

Synthesis of polymeric norspermine prodrug 14

The polymerization was first attempted with copolymerization with HPMA.
Briefly, HPMA, CTA, and AIBN were dissolved and mixed in methanol and monomer 13
was dissolved in water. The polymerization was carried out in water/methanol mixture
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at 65 °C (Scheme 4.5). After dialysis in 3500 MWCO against water and lyophilization, there
was no product. Then the homo-polymerization was carried out to investigate if the
polymer could successfully polymerize. Monomer 13 (0.10 g, 0.12 mmol) and AIBN (0.16
mg, 1.2 µmol) were mixed in water/methanol solution at 0.10 g/ml reaction mass
concentration followed by the same purification process and there was no product after
lyophilization.
With this result we concluded that, even though C-N bond was stable, without
carboxyl group, the polymerization ability would be greatly reduced and polymerization
with bulky groups like monomer 13 proved to be difficult. Thus, an alternative route to
synthesize the methacrylamide was developed based on the last scheme.
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Scheme 4.5 Synthesis of polymeric norspermine prodrug 14.
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4.3.6

Synthesis of norspermine monomer 19

Due to the facts that methacrylate was not stable enough and carbon nitrogen bond
could not polymerize, we had decided to establish a methacrylamide monomer (Scheme
4.6).

Scheme 4.6 Synthesis of compound 19.
4.3.6.1 Synthesis of compound 15

Methacrylic acid (MAA) (1.7 ml, 20 mmol), triethylamine (5.6 ml, 40 mmol) and
DMAP (0.49 g, 4.0 mmol) were dissolved in 60 ml chloroform followed by the addition of
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (5.7 g, 30 mmol) as catalyst. Then
propargylamine (1.5 ml, 24 mmol) was added in ice bath and the reaction was stirred
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overnight. The resulting product was washed by water and chloroform was removed
under reduced pressure. Compound 15 was finally purified by flash silica
chromatography as white solid (1.7 g, 68%) (Figure 4.8). 1H NMR (400MHz, CDCl3) δ 6.12
(bs, 1H), 5.74 (s, 1H), 5.38 (s, 1H), 4.11 (m, 2H), 2.26 (s, 1H), 1.98 (s, 3H).

Figure 4.8 1H NMR of compound 15 in CDCl3.
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4.3.6.2 Synthesis of compound 16

Compound 15 (0.25 g, 2.0 mol) and compound 9 (0.30 g, 1.7 mmol) were dissolved
in 10 ml methanol. Copper sulfate pentahydrate (32 mg, 0.13 mmol) was dissolved in 0.10
ml DI water and mixed with reaction mass. Then sodium ascorbate (80 mg, 0.40 mmol)
was dissolved in 0.10 ml DI water and added into the reaction mass. The click reaction
was allowed to stir at 40 °C overnight. The raw product was extracted ethyl acetate and
washed by water followed by the complete remove of the solvent under reduced pressure.
The final product was purified by silica chromatography at 5% methanol in DCM as white
solid (0.48 g, 94%) (Figure 4.9). 1H NMR (400MHz, CDCl3) δ 7.70 (s, 1H), 6.61 (bs, 1H), 5.76

Figure 4.9 1H NMR of compound 16 in CDCl3.
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(s, 1H), 5.38 (s, 1H), 4.69 (t, J=6.4Hz, 2H), 4.58 (d, J=5.6Hz, 2H), 3.88(t, J=6.0Hz, 2H), 3.20 (t,
J=6.8Hz, 2H), 2.89 (t, J=6.0Hz, 2H), 2.28 (bs, 1H), 1.98 (s, 3H).
4.3.6.3 Synthesis of compound 17-19

Synthesis procedures for norspermine coupling were the same as before.
Compound 17 (0.61 g, 97%) (Figure 4.10) 1H NMR (400MHz, CDCl3) δ 8.14 (s, 1H), 7.65 (s,
1H), 7.45 (s, 1H), 7.90 (s, 1H), 6.76 (bs, 1H), 5.75 (s, 1H), 5.36 (s, 1H), 5.31 (s, 2H), 4.67 (m,
4H), 4.57 (d, J=6.0Hz, 2H), 3.21 (t, J=6.8Hz, 2H), 3.09 (t, J=6.4Hz, 2H), 1.97 (s, 3H).
Compound 18 was synthesized by activating the compound 17 with CDI through
the previous process and further coupled with triboc-norspermine to obtain compound
19 (0.54 g, 98%) 1H NMR (400MHz, D2O) δ 7.93 (s, 1H), 5.67 (s, 1H), 5.43 (s, 1H), 4.49 (s,
1H), 4.21 (t, J=5.6 Hz, 2H), 3.25-3.01 (m, 14H), 2.83 (m, 2H), 2.06 (m, 4H), 1.84 (m, 5H).
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Figure 4.10 1H NMR of compound 17 in CDCl3 and compound 19 in D2O.
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4.3.7

Synthesis and characterization of polymeric norspermine prodrug 20

The polymer was successfully synthesized and the ability of the polymer to deliver
the gene was then evaluated to predict the gene delivery ability for BENSpm polymeric
prodrug that would be easily synthesized with these schemes.
4.3.7.1 Synthesis of polymeric norpsermine prodrug hPNP and cPNP

The homo-polymerization and co-polymerization of compound 19 were
synthesized by RAFT polymerization (Scheme 4.7). Briefly, compound 19 (76 mg, 0.13
mmol) with or without HPMA (24 mg, 0.17 mmol) were mixed with PEG RAFT CTA (7.2
mg, 3.0 µmol) and 4,4'-azobis (4-cyanopentanoic acid) (ACVA) (1.0 mg, 3.6 µmol) in
water/methanol. The reaction was stirred for 24 h at 70 °C. The raw products were
dialyzed against 0.1% HCl solution for 1 day and switched DI water for another day.
Water was removed by lyophilization to obtain homo-polymerized norspermine prodrug
(hPNP) and co-polymerized norspermine prodrug (cPNP). The molar and weight content
of norspermine was calculated according to 1H NMR (Figure 4.11). The molecular weights
of the polymers were evaluated by GPC, which were summarized in table 4.1.
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Scheme 4.7 Synthesis of cPNP.
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Figure 4.11 1H NMR of cPNP and hPNP in D2O.
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Table 4.1 Characterization of the cPNP and hPNP.

The peaks from δ 7.93 ppm were from the triazole group of the monomer 19
demonstrated the intact of the monomer and could be used to determine the molar ratio
of the BENSpm. The extra peak at δ 3.86 ppm compared with hPNP obviously came from
HPMA which was used to calculate the molar ratio of HPMA. Since the molecular weight
of the PEG was known as 2 KDa in CTA, the molecular weight of the polymer could be
calculated based on the molar ratio of different components in the polymer. The molecular
weight of the polymers calculated from the NMR was about 20 KDa which was close to
the targeting in feed molecular weight as 30 KDa. However, the GPC data was not
consistent with the NMR calculation probably due to the highly crosslinking nature of the
disulfide bond. And the resulting products would crosslink when stored under room
temperature leading to the insolubility in any solvent. For hPNP, with high drug loading
yet high disulfide content, could crosslink after overnight at room temperature.
4.3.7.2 Characterization of hPNP/siRNA and cPNP/siRNA nanoparticles

The ability of the polymers to condense the siRNA was evaluated in agarose gel
electrophoresis. Different w/w ratios of polymer to siRNA ratio was prepared by mixing
polymers at different concentrations with siRNA solutions in 10 mM HEPES buffer (pH =
7.4). The solution was incubated at room temperature for 30 mins to obtain gene loaded
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nanoparticles. The resulting nanoparticles were loaded into 1.8% agarose gel containing
0.5 µg/ml ethidium bromide. The gel was run in 0.5X Tris/Borate/EDTA buffer at 110 V
for 15 mins and visualized with KPDAK Gel Logic 100 imaging system. Hydrodynamic
size and zeta-potential were determined by dynamic light scattering (DLS) with
NanoBrook Omni (Brookhaven instruments, NY). SiRNA release from the nanoparticles
was evaluated with heparin displacement assay. The nanoparticles at w/w = 5 were
incubated at different heparin concentrations with or without 20 mM glutathione (GSH)
for 30 mins at 37°C followed by the analysis described above (Figure 4.12).
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Figure 4.12 Characterization of hPNP/siRNA and cPNP/siRNA nanoparticles. (A)
siRNA condensation of hPNP and cPNP at different w/w ratio by gel electrophoresis.
(B) Hydrodynamic size and PDI of the cPNP/siRNA at different w/w ratio. (C) Zetapotential of the hPNP/siRNA nanoparticles. (D) Heparin and GSH induced RNA
release from hPNP/siRNA and cPNP/siRNA. Nanoparticles were incubated with
different heparin concentrations with or without GSH for 30 mins at 37 °C.
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Both polycationic polymers can successfully condense the siRNA at w/w>2.5. Due
to the crosslinking nature, part of the hPNP was insoluble in water, which leaded to
reduced concentration in solution and increased w/w ratio for full RNA condensation.
The size of the nanoparticles was in nanometer range with highly positively charged zetapotential as about 20 mV. Since the degradation of the disulfide should release
norspermine and breakdown the polymer, the loaded siRNA should also be released since
norspermine had no siRNA condensation ability. To verify that the ability of the
polymer/siRNA complex can release the siRNA under reductive condition, we compared
the heparin stability of the nanoparticles at the presence of the GSH. The hPNP/siRNA
showed better stability against heparin and no siRNA release was observed until 80 µg/ml
heparin concentration. However, when incubated with GSH for only 30 mins, the
nanoparticles were destabilized, and siRNA was release with much less heparin
concentration. Those results indicated the successful synthesis of the GSH responsive
polymers which can reversibly condense the siRNA.
4.3.7.3 Cellular uptake of hPNP/siRNA and cPNP/siRNA nanoparticles

Murine melanoma cell line B16F10 was grown in RPMI-1640 supplemented with
10% fetal bovine serum (FBS) and penicillin (100 U/ml)-streptomycin (100 U/ml) at 37°C
with 5% CO2 in humidified chamber.
Cells were seeded in 12 well plates and incubated 24 h for cells to attach. Cells
were treated with different formulations containing 100 nM Cy5-siRNA or FITC-siRNA
for 4hrs in serum free medium. Cells were washed with PBS and then detached with
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tripLE. Cell suspensions were analyzed by LSR II (BD Biosciences, MA). The results were
processed by FlowJo software.
To evaluate the RNA delivery efficacy of the nanoparticles, flow cytometry was
applied to quantify the intracellular RNA content using fluorescent siRNA (cy5-siRNA
and FITC-siRNA). Different w/w ratio of cPNP/siRNA were incubated with cells for 4 h
to find the optimized ratio. PEI/siRNA as the gold standard for siRNA delivery was used
as a positive control. As shown in figure 4.13, at w/w = 5, cPNP/siRNA showed the highest
mean fluorescent intensity (MFI) per cell indicated the optimized ratio for the further
study. Although there was almost 100% cell uptake in PEI group and other two PNP
groups, at w/w = 5 both nanoparticles proved to be more efficient for intracellular siRNA
delivery in MFI than PEI/siRNA likely due to the high molecular weight of the polymers.
Homo polymerized polymer hPNP/siRNA showed highest MFI which was about 3-fold
as the cPNP/siRNA probably due to the higher amine concentration.
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4.4

Conclusion

In summary, a monomer that could be able to polymerize with stability in acid
condition was synthesized after multiple attempts and the polymeric norspermine
prodrug was finally synthesized through RAFT polymerization with high norspermine
loading. Of the two synthesized polymers, the gene loading and siRNA delivery of the
polymers were tested. Both polymers demonstrated reversible siRNA binding and
excellent siRNA cellular uptake compared with PEI. HPNP showed not only high drug
loading but also high siRNA delivery efficiency. Overall, those results provided impetus
for further synthesis of the polymeric BENSpm prodrug through the same scheme for
gene delivery system. Moreover, since the polymer was synthesized through RAFT
polymerization, co-polymerization with other functional groups like methacrylamide
PEG or methacrylamide perfluorocarbon could be easily achieved.
Chapter 5. Summary and future direction

Cancer is a worldwide health challenge for years with 10 million cancer death
occurred in 2020. Although the diagnosis and treatment methods are improving, the
current treatment still suffers from limited efficacy and severe side effects. Furthermore,
the heterogeneity in the tumor due to the process of gene mutation and tumor evolution
has made the treatment of cancer even more difficult.
RNAi is a novel therapeutic modality that requires the development of effective
delivery vectors due to the unfavorable biopharmaceutical properties of RNA. The use of
polycationic non-viral vectors have been an attractive strategy for siRNA delivery due to
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their versatility and safety profile. The complexation of cationic vectors with anionic
siRNA forms nanoparticles. As novel treatment method, nanoparticles has shown to
reduce mortality and improve efficacy in cancer treatment. Recently, the nanoparticles
developed to simultaneously deliver drug/siRNA to target different oncogenic pathways
in tumor can overcome the resistance of monotherapy leading to improved therapeutic
outcome.
Polyamines, ubiquitously present in all tissues and all cell types, are essential
organic polycations involved in many vital processes of cell proliferation and apoptosis.
The dysregulated polyamine metabolism due to multiple convoluted oncogenic pathways
leads to increased intracellular polyamine concentration which supports the cancer cell
growth. Thus, targeting the polyamine metabolism for downregulation of polyamine
concentration in cancer cells is an intriguing strategy. Although countless compounds
have been developed as chemotherapeutic drug targeting polyamine metabolism, none
was found effective in clinical trials. The most successful compound, BENSpm, showed
only stable disease as the best observed clinical result. Taking advantage of the role of
polyamines and therapeutic potential of siRNA, we developed a polymeric prodrug based
on BENSpm as siRNA delivery vector. PLK1 is a serine threonine kinase required for
regulation of mitosis that is overexpressed in many types of cancer. Thus, siPLK1 was
selected to load into the polyplex for combinational therapy. To further enhance its
biocompatibility, transfection and targeting effect of the system, fluorine was introduced
in the polymer and HA was coated on the polyplex. This ternary complex was tested on
colorectal cell lines and pancreatic cell line and demonstrated reduced toxicity to the
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membrane, improved gene silencing effect in vitro. In the orthotopic pancreatic cancer
model, the HA@F-PaP/siRNA showed selective accumulation in tumor due to the CD44
targeting effect of HA. These favorable results promoted us to investigate the therapeutic
effects. As expected, the HA@F-PaP/siPLK1 significantly inhibited tumor growth by
polyamine catabolism induction and PLK1 knockdown. The study showed that we have
successfully developed the polymeric prodrug to achieve the simultaneous delivery of
drug and siRNA.
Curcumin is a natural phenolic compound extracted from turmeric that has been
used as spice and dietary supplements for centuries. Recent study showed that curcumin
had multiple pharmacological activities including anti-cancer activity. Curcumin was also
reported as polyamine metabolism regulator in colorectal cancer. By upregulating the
polyamine catabolic rate limiting enzymes (SSAT and SMOX) and down regulating the
synthetic rate limiting enzymes (ODC and AdoMetDC), curcumin can reduce cancer cell
polyamine concentration. Although curcumin can regulate multiple pathways to inhibit
cancer growth, its bioavailability is limited to achieve its therapeutic effects due to its
insolubility in aqueous solution. Mutations in Kras accounts for more than 40% for
colorectal cancer associated with disease progression, metastasis, and survival, making
Kras a perfect target for colorectal cancer. Mutated Kras also activates ODC expression
while inhibit SSAT expression implying the increase of cell polyamine concentration for
cancer proliferation. We designed a lipoplex for co-delivery of curcumin and siKras as
combinational treatment against colorectal cancer. To improve the siRNA delivery of
lipoplex, folic acid was conjugated into the lipoplex. The combinational therapy of
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curcumin and siKras demonstrated anti-migration, anti-proliferative and apoptosis
inducing effects.
We have been trying to synthesize tunable polymeric prodrug by RAFT
polymerization. To achieve this, our first step was to synthesized monomers with
immolative linker and alkene group with norspermine. Our pilot data suggested that
polymeric norspermine prodrug (PNP) had excellent siRNA condensation ability and cell
uptake. This prodrug synthesis route could be applied to any other drugs containing
amines and modification of this prodrug system with other moieties can be easily
achieved by simply using RAFT polymerization with other acrylamides.
Based on our previous studies, we propose to develop polymeric BENSpm
prodrug by RAFT polymerization with the similar synthesis route as our future directions.
This prodrug system will be equipped with fluoroalkyl and targeting moiety (iRGD,
hyaluronic acid, tumor penetrating peptides and so on). First, the acrylamide monomer
with immolative linker and BENSpm will be synthesized. Then chain transfer agent with
targeting moiety is synthesized. Prodrug polymers with low and high fluorine content
and molecular weight will be synthesized by RAFT polymerization which is difficult to
control by step polymerization. Then a series of polymers with different fluorine content
can be obtained by simply mixing the two polymers at different ratio. The best fluorine
ratio will be selected based on stability and RNA delivery efficacy. This polymer can be
further tested in vivo for therapeutic efficacy.

132
Bibliography
[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA: A Cancer Journal for
Clinicians 69(1) (2019) 7-34.
[2] H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray,
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians 71(3)
(2021) 209-249.
[3] K.D. Miller, L. Nogueira, A.B. Mariotto, J.H. Rowland, K.R. Yabroff, C.M. Alfano, A.
Jemal, J.L. Kramer, R.L. Siegel, Cancer treatment and survivorship statistics, 2019, CA: A
Cancer Journal for Clinicians 69(5) (2019) 363-385.
[4] M. Nikolaou, A. Pavlopoulou, A.G. Georgakilas, E. Kyrodimos, The challenge of
drug resistance in cancer treatment: a current overview, Clinical & Experimental
Metastasis 35(4) (2018) 309-318.
[5] M.M. Gottesman, Mechanisms of Cancer Drug Resistance, Annual Review of Medicine
53(1) (2002) 615-627.
[6] V. Schirrmacher, From chemotherapy to biological therapy: A review of novel concepts
to reduce the side effects of systemic cancer treatment (Review), Int J Oncol 54(2) (2019)
407-419.

133
[7] L. Warrington, K. Absolom, M. Conner, I. Kellar, B. Clayton, M. Ayres, G. Velikova,
Electronic Systems for Patients to Report and Manage Side Effects of Cancer Treatment:
Systematic Review, J Med Internet Res 21(1) (2019) e10875.
[8] A. Pearce, M. Haas, R. Viney, S.-A. Pearson, P. Haywood, C. Brown, R. Ward, Incidence
and severity of self-reported chemotherapy side effects in routine care: A prospective
cohort study, PLOS ONE 12(10) (2017) e0184360.
[9] N. McGranahan, C. Swanton, Biological and Therapeutic Impact of Intratumor
Heterogeneity in Cancer Evolution, Cancer Cell 27(1) (2015) 15-26.
[10] S. Turajlic, A. Sottoriva, T. Graham, C. Swanton, Resolving genetic heterogeneity in
cancer, Nature Reviews Genetics 20(7) (2019) 404-416.
[11] S. Tran, P.-J. DeGiovanni, B. Piel, P. Rai, Cancer nanomedicine: a review of recent
success in drug delivery, Clinical and Translational Medicine 6(1) (2017) 44.
[12] E. Casals, M.F. Gusta, M. Cobaleda-Siles, A. Garcia-Sanz, V.F. Puntes, Cancer
resistance to treatment and antiresistance tools offered by multimodal multifunctional
nanoparticles, Cancer Nanotechnology 8(1) (2017) 7.
[13] D. Kim, K. Shin, S.G. Kwon, T. Hyeon, Synthesis and Biomedical Applications of
Multifunctional Nanoparticles, Advanced Materials 30(49) (2018) 1802309.
[14] P. Cao, Y. Bae, Polymer nanoparticulate drug delivery and combination cancer
therapy, Future Oncology 8(11) (2012) 1471-1480.

134
[15] T. Ahmadzada, G. Reid, D.R. McKenzie, Fundamentals of siRNA and miRNA
therapeutics and a review of targeted nanoparticle delivery systems in breast cancer,
Biophysical Reviews 10(1) (2018) 69-86.
[16] J. Li, F. Yu, Y. Chen, D. Oupický, Polymeric drugs: Advances in the development of
pharmacologically active polymers, Journal of Controlled Release 219 (2015) 369-382.
[17] K. Tatiparti, S. Sau, S.K. Kashaw, A.K. Iyer, siRNA Delivery Strategies: A
Comprehensive Review of Recent Developments, Nanomaterials 7(4) (2017).
[18] F. Sánchez-Jiménez, M.Á. Medina, L. Villalobos-Rueda, J.L. Urdiales, Polyamines in
mammalian pathophysiology, Cellular and Molecular Life Sciences 76(20) (2019) 39874008.
[19] E.M. Levasseur, K. Yamada, A.R. Piñeros, W. Wu, F. Syed, K.S. Orr, E. AndersonBaucum, T.L. Mastracci, B. Maier, A.L. Mosley, Y. Liu, E. Bernal-Mizrachi, L.C. Alonso, D.
Scott, A. Garcia-Ocaña, S.A. Tersey, R.G. Mirmira, Hypusine biosynthesis in β cells links
polyamine metabolism to facultative cellular proliferation to maintain glucose
homeostasis, Science Signaling 12(610) (2019) eaax0715.
[20] R.A. Casero, T. Murray Stewart, A.E. Pegg, Polyamine metabolism and cancer:
treatments, challenges and opportunities, Nature Reviews Cancer 18(11) (2018) 681-695.
[21] R.A. Casero, L.J. Marton, Targeting polyamine metabolism and function in cancer and
other hyperproliferative diseases, Nature Reviews Drug Discovery 6(5) (2007) 373-390.

135
[22] A.K. Handa, T. Fatima, A.K. Mattoo, Polyamines: Bio-Molecules with Diverse
Functions in Plant and Human Health and Disease, Frontiers in Chemistry 6(10) (2018).
[23] V. Norris, R.N. Reusch, K. Igarashi, R. Root-Bernstein, Molecular complementarity
between simple, universal molecules and ions limited phenotype space in the precursors
of cells, Biology Direct 10(1) (2014) 28.
[24] S. Mandal, A. Mandal, Myung H. Park, Depletion of the polyamines spermidine and
spermine by overexpression of spermidine/spermine N1-acetyltransferase 1 (SAT1) leads
to mitochondria-mediated apoptosis in mammalian cells, Biochemical Journal 468(3)
(2015) 435-447.
[25] P.R. Stanfield , M.J. Sutcliffe Spermine Is Fit to Block Inward Rectifier (Kir) Channels,
Journal of General Physiology 122(5) (2003) 481-484.
[26] A.E. Pegg, Functions of Polyamines in Mammals *, Journal of Biological Chemistry
291(29) (2016) 14904-14912.
[27] G. Iacomino, G. Picariello, L. D'Agostino, DNA and nuclear aggregates of polyamines,
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823(10) (2012) 1745-1755.
[28] M.-H. Hou, S.-B. Lin, J.-M.P. Yuann, W.-C. Lin, A.H.J. Wang, L.-s. Kan, Effects of
polyamines on the thermal stability and formation kinetics of DNA duplexes with
abnormal structure, Nucleic Acids Research 29(24) (2001) 5121-5128.
[29] S. Venkiteswaran, V. Vijayanathan, A. Shirahata, T. Thomas, T.J. Thomas, Antisense
Recognition of the HER-2 mRNA: Effects of Phosphorothioate Substitution and

136
Polyamines on DNA·RNA, RNA·RNA, and DNA·DNA Duplex Stability, Biochemistry
44(1) (2005) 303-312.
[30] A. Kanemura, Y. Yoshikawa, W. Fukuda, K. Tsumoto, T. Kenmotsu, K. Yoshikawa,
Opposite effect of polyamines on In vitro gene expression: Enhancement at low
concentrations but inhibition at high concentrations, PLOS ONE 13(3) (2018) e0193595.
[31] Y. Terui, T. Yoshida, A. Sakamoto, D. Saito, T. Oshima, M. Kawazoe, S. Yokoyama, K.
Igarashi, K. Kashiwagi, Polyamines protect nucleic acids against depurination, The
International Journal of Biochemistry & Cell Biology 99 (2018) 147-153.
[32] A. Sakamoto, Y. Terui, T. Yoshida, T. Yamamoto, H. Suzuki, K. Yamamoto, A.
Ishihama, K. Igarashi, K. Kashiwagi, Three Members of Polyamine Modulon under
Oxidative Stress Conditions: Two Transcription Factors (SoxR and EmrR) and a
Glutathione Synthetic Enzyme (GshA), PLOS ONE 10(4) (2015) e0124883.
[33] K. Igarashi, K. Kashiwagi, The functional role of polyamines in eukaryotic cells, The
International Journal of Biochemistry & Cell Biology 107 (2019) 104-115.
[34] H.L. Lightfoot, J. Hall, Endogenous polyamine function—the RNA perspective,
Nucleic Acids Research 42(18) (2014) 11275-11290.
[35] D. Konecki, G. Kramer, P. Pinphanichakarn, B. Hardesty, Polyamines are necessary
for maximum in vitro synthesis of globin peptides and play a role in chain initiation, Arch
Biochem Biophys 169(1) (1975) 192-98.

137
[36] K. Igarashi, K. Hikami, K. Sugawara, S. Hirose, Effect of polyamines on polypeptide
synthesis in rat liver cell-free system, Biochim Biophys Acta 299(2) (1973) 325-30.
[37] K. Igarashi, K. Kashiwagi, Modulation of protein synthesis by polyamines, IUBMB
Life 67(3) (2015) 160-169.
[38] T. Ogasawara, K. Ito, K. Igarashi, Effect of Polyamines on Globin Synthesis in a Rabbit
Reticulocyte Rolyamine-Free Protein Synthetic System, The Journal of Biochemistry 105(2)
(1989) 164-167.
[39] K. Igarashi, K. Kashiwagi, Polyamine Modulon in Escherichia coli: Genes Involved in
the Stimulation of Cell Growth by Polyamines, The Journal of Biochemistry 139(1) (2006)
11-16.
[40] K. Nishimura, H. Okudaira, E. Ochiai, K. Higashi, M. Kaneko, I. Ishii, T. Nishimura,
N. Dohmae, K. Kashiwagi, K. Igarashi, Identification of proteins whose synthesis is
preferentially enhanced by polyamines at the level of translation in mammalian cells, The
International Journal of Biochemistry & Cell Biology 41(11) (2009) 2251-2261.
[41] K. Igarashi, K. Kashiwagi, Characterization of genes for polyamine modulon,
Methods Mol Biol 720 (2011) 51-65.
[42] Y. Terui, A. Sakamoto, T. Yoshida, T. Kasahara, H. Tomitori, K. Higashi, K. Igarashi,
K. Kashiwagi, Polyamine stimulation of eEF1A synthesis based on the unusual position
of a complementary sequence to 18S rRNA in eEF1A mRNA, Amino Acids 47(2) (2015)
345-356.

138
[43] S. Matsufuji, T. Matsufuji, Y. Miyazaki, Y. Murakami, J.F. Atkins, R.F. Gesteland, S.-i.
Hayashi, Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase
antizyme, Cell 80(1) (1995) 51-60.
[44] A.P. Schuller, C.C.-C. Wu, T.E. Dever, A.R. Buskirk, R. Green, eIF5A Functions
Globally in Translation Elongation and Termination, Molecular Cell 66(2) (2017) 194205.e5.
[45] E. Gutierrez, B.-S. Shin, Christopher J. Woolstenhulme, J.-R. Kim, P. Saini, Allen R.
Buskirk, Thomas E. Dever, eIF5A Promotes Translation of Polyproline Motifs, Molecular
Cell 51(1) (2013) 35-45.
[46] L.K. Doerfel, I. Wohlgemuth, C. Kothe, F. Peske, H. Urlaub, M.V. Rodnina, EF-P Is
Essential for Rapid Synthesis of Proteins Containing Consecutive Proline Residues,
Science 339(6115) (2013) 85.
[47] M.H. Park, K. Nishimura, C.F. Zanelli, S.R. Valentini, Functional significance of eIF5A
and its hypusine modification in eukaryotes, Amino Acids 38(2) (2010) 491-500.
[48] M. Caraglia, M.H. Park, E.C. Wolff, M. Marra, A. Abbruzzese, eIF5A isoforms and
cancer: two brothers for two functions?, Amino Acids 44(1) (2013) 103-9.
[49] M.B. Mathews, J.W.B. Hershey, The translation factor eIF5A and human cancer,
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1849(7) (2015) 836844.

139
[50] H.M. WALLACE, A.V. FRASER, A. HUGHES, A perspective of polyamine
metabolism, Biochemical Journal 376(1) (2003) 1-14.
[51] Robert A. Casero, Jr, Anthony E. Pegg, Polyamine catabolism and disease,
Biochemical Journal 421(3) (2009) 323-338.
[52] A.E. Pegg, Toxicity of Polyamines and Their Metabolic Products, Chemical Research
in Toxicology 26(12) (2013) 1782-1800.
[53] A.J. Palmer, H.M. Wallace, The polyamine transport system as a target for anticancer
drug development, Amino Acids 38(2) (2010) 415-422.
[54] N.N. Hamouda, C. Van den Haute, R. Vanhoutte, R. Sannerud, M. Azfar, R. Mayer,
Á. Cortés Calabuig, J.V. Swinnen, P. Agostinis, V. Baekelandt, W. Annaert, F. Impens,
S.H.L. Verhelst, J. Eggermont, S. Martin, P. Vangheluwe, ATP13A3 is a major component
of the enigmatic mammalian polyamine transport system, Journal of Biological Chemistry
296 (2021).
[55] D. Wu, H.Y.K. Kaan, X. Zheng, X. Tang, Y. He, Q. Vanessa Tan, N. Zhang, H. Song,
Structural basis of Ornithine Decarboxylase inactivation and accelerated degradation by
polyamine sensor Antizyme1, Scientific Reports 5(1) (2015) 14738.
[56] H.-Y. Wu, S.-F. Chen, J.-Y. Hsieh, F. Chou, Y.-H. Wang, W.-T. Lin, P.-Y. Lee, Y.-J. Yu,
L.-Y. Lin, T.-S. Lin, C.-L. Lin, G.-Y. Liu, S.-R. Tzeng, H.-C. Hung, N.-L. Chan, Structural
basis of antizyme-mediated regulation of polyamine homeostasis, Proceedings of the
National Academy of Sciences 112(36) (2015) 11229.

140
[57] B. Ramos-Molina, A. Lambertos, R. Peñafiel, Antizyme Inhibitors in Polyamine
Metabolism and Beyond: Physiopathological Implications, Medical Sciences 6(4) (2018) 89.
[58] A.E. Pegg, Mammalian polyamine metabolism and function, IUBMB Life 61(9) (2009)
880-894.
[59] T.E. Dever, I.P. Ivanov, Roles of polyamines in translation, Journal of Biological
Chemistry 293(48) (2018) 18719-18729.
[60] C. Kahana, Ubiquitin dependent and independent protein degradation in the
regulation of cellular polyamines, Amino Acids 33(2) (2007) 225-230.
[61] N.J. Butcher, G.M. Broadhurst, R.F. Minchin, Polyamine-dependent Regulation of
Spermidine-Spermine <em>N</em><sup>1</sup>-Acetyltransferase mRNA Translation
*<sup></sup>, Journal of Biological Chemistry 282(39) (2007) 28530-28539.
[62] O. Perez-Leal, S. Merali, Regulation of polyamine metabolism by translational control,
Amino Acids 42(2-3) (2012) 611-7.
[63] N.J. Butcher, G.M. Broadhurst, R.F. Minchin, Polyamine-dependent regulation of
spermidine-spermine N1-acetyltransferase mRNA translation, J Biol Chem 282(39) (2007)
28530-28539.
[64] M.T. Hyvönen, A. Uimari, T.A. Keinänen, S. Heikkinen, R. Pellinen, T. Wahlfors, A.
Korhonen, A. Närvänen, J. Wahlfors, L. Alhonen, J. Jänne, Polyamine-regulated
unproductive splicing and translation of spermidine/spermine N1-acetyltransferase, Rna
12(8) (2006) 1569-82.

141
[65] L. Persson, Polyamine homoeostasis, Essays in Biochemistry 46 (2009) 11-24.
[66] O. Perez-Leal, C.A. Barrero, A.B. Clarkson, R.A. Casero, Jr., S. Merali, Polyamineregulated translation of spermidine/spermine-N1-acetyltransferase, Mol Cell Biol 32(8)
(2012) 1453-67.
[67] M. Corral, H.M. Wallace, Upregulation of Polyamine Transport in Human Colorectal
Cancer Cells, Biomolecules 10(4) (2020).
[68] T. Thomas, T.J. Thomas, Polyamine metabolism and cancer, Journal of Cellular and
Molecular Medicine 7(2) (2003) 113-126.
[69] A.E. Pegg, Polyamine Metabolism and Its Importance in Neoplastic Growth and as a
Target for Chemotherapy, Cancer Research 48(4) (1988) 759-774.
[70] T.R. Murray-Stewart, P.M. Woster, R.A. Casero, Jr, Targeting polyamine metabolism
for cancer therapy and prevention, Biochemical Journal 473(19) (2016) 2937-2953.
[71] I. Novita Sari, T. Setiawan, K. Seock Kim, Y. Toni Wijaya, K. Won Cho, H. Young
Kwon, Metabolism and function of polyamines in cancer progression, Cancer Letters 519
(2021) 91-104.
[72] A. Arruabarrena-Aristorena, A. Zabala-Letona, A. Carracedo, Oil for the cancer
engine: The cross-talk between oncogenic signaling and polyamine metabolism, Science
Advances 4(1) (2018) eaar2606.
[73] S. Li, A. Balmain, C.M. Counter, A model for RAS mutation patterns in cancers:
finding the sweet spot, Nature Reviews Cancer 18(12) (2018) 767-777.

142
[74] L.M. SHANTZ, Transcriptional and translational control of ornithine decarboxylase
during Ras transformation, Biochemical Journal 377(1) (2004) 257-264.
[75] E.W. Gerner, F.L. Meyskens, Polyamines and cancer: old molecules, new
understanding, Nature Reviews Cancer 4(10) (2004) 781-792.
[76] L. Soucek, J. Whitfield, C.P. Martins, A.J. Finch, D.J. Murphy, N.M. Sodir, A.N.
Karnezis, L.B. Swigart, S. Nasi, G.I. Evan, Modelling Myc inhibition as a cancer therapy,
Nature 455(7213) (2008) 679-683.
[77] A.S. Bachmann, D. Geerts, Polyamine synthesis as a target of <em>MYC</em>
oncogenes, Journal of Biological Chemistry 293(48) (2018) 18757-18769.
[78] T.P. Forshell, S. Rimpi, J.A. Nilsson, Chemoprevention of B-Cell Lymphomas by
Inhibition of the Myc Target Spermidine Synthase, Cancer Prevention Research 3(2) (2010)
140.
[79] D.A. Fruman, C. Rommel, PI3K and cancer: lessons, challenges and opportunities,
Nature Reviews Drug Discovery 13(2) (2014) 140-156.
[80] V. Rajeeve, W. Pearce, M. Cascante, B. Vanhaesebroeck, Pedro R. Cutillas, Polyamine
production is downstream and upstream of oncogenic PI3K signalling and contributes to
tumour cell growth, Biochemical Journal 450(3) (2013) 619-628.
[81] J.C. Chamcheu, T. Roy, M.B. Uddin, S. Banang-Mbeumi, R.-C.N. Chamcheu, A.L.
Walker, Y.-Y. Liu, S. Huang, Role and Therapeutic Targeting of the PI3K/Akt/mTOR

143
Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on
Natural and Synthetic Agents Therapy, Cells 8(8) (2019) 803.
[82] Y. Ou, S.-J. Wang, D. Li, B. Chu, W. Gu, Activation of &lt;em&gt;SAT1&lt;/em&gt;
engages polyamine metabolism with p53-mediated ferroptotic responses, Proceedings of
the National Academy of Sciences 113(44) (2016) E6806.
[83] K. Yamamoto, A. Venida, J. Yano, D.E. Biancur, M. Kakiuchi, S. Gupta, A.S.W. Sohn,
S. Mukhopadhyay, E.Y. Lin, S.J. Parker, R.S. Banh, J.A. Paulo, K.W. Wen, J. Debnath, G.E.
Kim, J.D. Mancias, D.T. Fearon, R.M. Perera, A.C. Kimmelman, Autophagy promotes
immune evasion of pancreatic cancer by degrading MHC-I, Nature 581(7806) (2020) 100105.
[84] J. Miska, A. Rashidi, C. Lee-Chang, P. Gao, A. Lopez-Rosas, P. Zhang, R. Burga, B.
Castro, T. Xiao, Y. Han, D. Hou, S. Sampat, A. Cordero, J.S. Stoolman, C.M. Horbinski, M.
Burns, Y.K. Reshetnyak, N.S. Chandel, M.S. Lesniak, Polyamines drive myeloid cell
survival by buffering intracellular pH to promote immunosuppression in glioblastoma,
Science Advances 7(8) (2021) eabc8929.
[85] C.S. Hayes, M.R. Burns, S.K. Gilmour, Polyamine blockade promotes antitumor
immunity, OncoImmunology 3(1) (2014) e27360.
[86] M. Selamnia, C. Mayeur, V. Robert, F. Blachier, α-Difluoromethylornithine (DFMO)
as a Potent Arginase Activity Inhibitor in Human Colon Carcinoma Cells, Biochemical
Pharmacology 55(8) (1998) 1241-1245.

144
[87] M. Zhang, H. Wang, K.J. Tracey, Regulation of macrophage activation and
inflammation by spermine: A new chapter in an old story, Critical Care Medicine 28(4)
(2000).
[88] S. Zhu, M. Ashok, J. Li, W. Li, H. Yang, P. Wang, K.J. Tracey, A.E. Sama, H. Wang,
Spermine Protects Mice Against Lethal Sepsis Partly by Attenuating Surrogate
Inflammatory Markers, Molecular Medicine 15(7) (2009) 275-282.
[89] N. Seiler, Thirty Years of Polyamine-Related Approaches to Cancer Therapy.
Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors, Current Drug Targets 4(7)
(2003) 537-564.
[90] H.M. Wallace, K. Niiranen, Polyamine analogues – an update, Amino Acids 33(2)
(2007) 261-265.
[91] H.M. Wallace, A.V. Fraser, Inhibitors of polyamine metabolism: review article, Amino
Acids 26(4) (2004) 353-65.
[92] K.P. Raj, J.A. Zell, C.L. Rock, C.E. McLaren, C. Zoumas-Morse, E.W. Gerner, F.L.
Meyskens,

Role

of

dietary

polyamines

in

a

phase

III

clinical

trial

of

difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal
adenomas, British Journal of Cancer 108(3) (2013) 512-518.
[93] E.T. Alexander, A. Minton, M.C. Peters, O.t. Phanstiel, S.K. Gilmour, A novel
polyamine blockade therapy activates an anti-tumor immune response, Oncotarget 8(48)
(2017) 84140-84152.

145
[94] C.S. Hayes, A.C. Shicora, M.P. Keough, A.E. Snook, M.R. Burns, S.K. Gilmour,
Polyamine-Blocking

Therapy

Reverses

Immunosuppression

in

the

Tumor

Microenvironment, Cancer Immunology Research 2(3) (2014) 274-285.
[95] E.T. Alexander, K. Mariner, J. Donnelly, O. Phanstiel, S.K. Gilmour, Polyamine
Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid
Cells and Enhances the Antitumor Efficacy of PD-1 Blockade, Molecular Cancer
Therapeutics 19(10) (2020) 2012-2022.
[96] L.J. Marton, A.E. Pegg, Polyamines as targets for therapeutic intervention, Annu Rev
Pharmacol Toxicol 35 (1995) 55-91.
[97] G. Bistulfi, H.C. Affronti, B.A. Foster, E. Karasik, B. Gillard, C. Morrison, J. Mohler,
J.G. Phillips, D.J. Smiraglia, The essential role of methylthioadenosine phosphorylase in
prostate cancer, Oncotarget 7(12) (2016) 14380-14393.
[98] L.M. Coussens, Z. Werb, Inflammation and cancer, Nature 420(6917) (2002) 860-867.
[99] V. Battaglia, C. DeStefano Shields, T. Murray-Stewart, R.A. Casero, Jr., Polyamine
catabolism in carcinogenesis: potential targets for chemotherapy and chemoprevention,
Amino acids 46(3) (2014) 511-519.
[100] A.C. Goodwin, C.E.D. Shields, S. Wu, D.L. Huso, X. Wu, T.R. Murray-Stewart, A.
Hacker-Prietz, S. Rabizadeh, P.M. Woster, C.L. Sears, R.A. Casero, Polyamine catabolism
contributes

to

enterotoxigenic

<em>Bacteroides

fragilis</em>-induced

colon

tumorigenesis, Proceedings of the National Academy of Sciences 108(37) (2011) 1535415359.

146
[101] E. Damiani, H.M. Wallace, Polyamines and Cancer, in: R. Alcázar, A.F. Tiburcio
(Eds.), Polyamines: Methods and Protocols, Springer New York, New York, NY, 2018, pp.
469-488.
[102] M.D.T. Senanayake, H. Amunugama, T.D. Boncher, R.A. Casero, Jr., P.M. Woster,
Design of polyamine-based therapeutic agents: new targets and new directions, Essays in
Biochemistry 46 (2009) 77-94.
[103] N. Seiler, Thirty Years of Polyamine-Related Approaches to Cancer Therapy.
Retrospect and Prospect. Part 2. Structural Analogues and Derivatives, Current Drug
Targets 4(7) (2003) 565-585.
[104] R.J. Bernacki, E.J. Oberman, K.E. Seweryniak, A. Atwood, R.J. Bergeron, C.W. Porter,
Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine
administered by multiple injection or continuous infusion, Clin Cancer Res 1(8) (1995)
847-57.
[105] R.A. Casero, Jr., S.J. Ervin, P. Celano, S.B. Baylin, R.J. Bergeron, Differential response
to treatment with the bis(ethyl)polyamine analogues between human small cell lung
carcinoma and undifferentiated large cell lung carcinoma in culture, Cancer Res 49(3)
(1989) 639-43.
[106] G.P. Zagaja, M. Shrivastav, M.J. Fleig, L.J. Marton, C.W. Rinker-Schaeffer, M.E.
Dolan, Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in
vivo, Cancer Chemother Pharmacol 41(6) (1998) 505-12.

147
[107] W.L. Allen, E.G. McLean, J. Boyer, A. McCulla, P.M. Wilson, V. Coyle, D.B. Longley,
R.A. Casero, P.G. Johnston, The role of spermidine/spermine <em>N</em><sup>1</sup>acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer
cells, Molecular Cancer Therapeutics 6(1) (2007) 128-137.
[108] B.K. Chang, R.J. Bergeron, C.W. Porter, Y. Liang, Antitumor effects ofN-alkylated
polyamine

analogues

in

human

pancreatic

adenocarcinoma

models,

Cancer

Chemotherapy and Pharmacology 30(3) (1992) 179-182.
[109] A.C. Wolff, D.K. Armstrong, J.H. Fetting, M.K. Carducci, C.D. Riley, J.F. Bender, R.A.
Casero, Jr., N.E. Davidson, A Phase II study of the polyamine analog N1,N11diethylnorspermine (DENSpm) daily for five days every 21 days in patients with
previously treated metastatic breast cancer, Clin Cancer Res 9(16 Pt 1) (2003) 5922-8.
[110] H.A. Hahm, D.S. Ettinger, K. Bowling, B. Hoker, T.L. Chen, Y. Zabelina, R.A. Casero,
Jr., Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung
cancer, Clin Cancer Res 8(3) (2002) 684-90.
[111] R.A. Casero, A.R. Mank, N.H. Saab, R. Wu, W.J. Dyer, P.M. Woster, Growth and
biochemical effects of unsymmetrically substituted polyamine analogues in human lung
tumor cells 1, Cancer Chemotherapy and Pharmacology 36(1) (1995) 69-74.
[112] R.A. Casero, P.M. Woster, Terminally Alkylated Polyamine Analogues as
Chemotherapeutic Agents, Journal of Medicinal Chemistry 44(1) (2001) 1-26.

148
[113] A. Hacker, L.J. Marton, M. Sobolewski, R.A. Casero, In vitro and in vivo effects of
the conformationally restricted polyamine analogue CGC-11047 on small cell and nonsmall cell lung cancer cells, Cancer Chemotherapy and Pharmacology 63(1) (2008) 45-53.
[114] T. Murray Stewart, A.A. Desai, M.L. Fitzgerald, L.J. Marton, R.A. Casero, Jr., A phase
I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid
tumors, Cancer Chemother Pharmacol 85(6) (2020) 1089-1096.
[115] T. Wirth, N. Parker, S. Ylä-Herttuala, History of gene therapy, Gene 525(2) (2013)
162-169.
[116] C.E. Dunbar, K.A. High, J.K. Joung, D.B. Kohn, K. Ozawa, M. Sadelain, Gene therapy
comes of age, Science 359(6372) (2018) eaan4672.
[117] Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products, Human
Gene Therapy 6(9) (1995) 1129-1144.
[118] D. Grimm, M.A. Kay, RNAi and Gene Therapy: A Mutual Attraction, Hematology
2007(1) (2007) 473-481.
[119] N.J. Caplen, Gene Therapy Progress and Prospects. Downregulating gene
expression: the impact of RNA interference, Gene Therapy 11(16) (2004) 1241-1248.
[120] S.E. Mohr, J.A. Smith, C.E. Shamu, R.A. Neumüller, N. Perrimon, RNAi screening
comes of age: improved techniques and complementary approaches, Nature Reviews
Molecular Cell Biology 15(9) (2014) 591-600.

149
[121] K. Lundstrom, Micro-RNA in Disease and Gene Therapy, Current Drug Discovery
Technologies 8(2) (2011) 76-86.
[122] N. Perrimon, J.Q. Ni, L. Perkins, In vivo RNAi: today and tomorrow, Cold Spring
Harb Perspect Biol 2(8) (2010) a003640.
[123] R.L. Setten, J.J. Rossi, S.-p. Han, The current state and future directions of RNAibased therapeutics, Nature Reviews Drug Discovery 18(6) (2019) 421-446.
[124] S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl, Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature
411(6836) (2001) 494-498.
[125] M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen,
J.D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA
via targeted nanoparticles, Nature 464(7291) (2010) 1067-1070.
[126] D.D. Rao, J.S. Vorhies, N. Senzer, J. Nemunaitis, siRNA vs. shRNA: Similarities and
differences, Advanced Drug Delivery Reviews 61(9) (2009) 746-759.
[127] J.K.W. Lam, M.Y.T. Chow, Y. Zhang, S.W.S. Leung, siRNA Versus miRNA as
Therapeutics for Gene Silencing, Molecular Therapy - Nucleic Acids 4 (2015) e252.
[128] M. Sioud, RNA Interference: Mechanisms, Technical Challenges, and Therapeutic
Opportunities, in: M. Sioud (Ed.), RNA Interference: Challenges and Therapeutic
Opportunities, Springer New York, New York, NY, 2015, pp. 1-15.

150
[129] D. Kim, J. Rossi, RNAi mechanisms and applications, Biotechniques 44(5) (2008) 613616.
[130] J. Stenvang, A. Petri, M. Lindow, S. Obad, S. Kauppinen, Inhibition of microRNA
function by antimiR oligonucleotides, Silence 3(1) (2012) 1-1.
[131] J.F. Lima, L. Cerqueira, C. Figueiredo, C. Oliveira, N.F. Azevedo, Anti-miRNA
oligonucleotides: A comprehensive guide for design, RNA Biology 15(3) (2018) 338-352.
[132] G. Tang, siRNA and miRNA: an insight into RISCs, Trends in Biochemical Sciences
30(2) (2005) 106-114.
[133] D. Siolas, C. Lerner, J. Burchard, W. Ge, P.S. Linsley, P.J. Paddison, G.J. Hannon,
M.A. Cleary, Synthetic shRNAs as potent RNAi triggers, Nature Biotechnology 23(2)
(2005) 227-231.
[134] P.J. Paddison, A.A. Caudy, E. Bernstein, G.J. Hannon, D.S. Conklin, Short hairpin
RNAs (shRNAs) induce sequence-specific silencing in mammalian cells, Genes Dev 16(8)
(2002) 948-58.
[135] P.N. Pushparaj, J.J. Aarthi, J. Manikandan, S.D. Kumar, siRNA, miRNA, and shRNA:
in vivo applications, J Dent Res 87(11) (2008) 992-1003.
[136] C.V. Pecot, G.A. Calin, R.L. Coleman, G. Lopez-Berestein, A.K. Sood, RNA
interference in the clinic: challenges and future directions, Nature Reviews Cancer 11(1)
(2011) 59-67.

151
[137] N. Agrawal, P.V. Dasaradhi, A. Mohmmed, P. Malhotra, R.K. Bhatnagar, S.K.
Mukherjee, RNA interference: biology, mechanism, and applications, Microbiol Mol Biol
Rev 67(4) (2003) 657-85.
[138] A.J. Pratt, I.J. MacRae, The RNA-induced silencing complex: a versatile genesilencing machine, The Journal of biological chemistry 284(27) (2009) 17897-17901.
[139] D.J. Taxman, C.B. Moore, E.H. Guthrie, M.T.-H. Huang, Short Hairpin RNA
(shRNA): Design, Delivery, and Assessment of Gene Knockdown, in: M. Sioud (Ed.), RNA
Therapeutics: Function, Design, and Delivery, Humana Press, Totowa, NJ, 2010, pp. 139156.
[140] M.K. Riley, W. Vermerris, Recent Advances in Nanomaterials for Gene Delivery—
A Review, Nanomaterials 7(5) (2017).
[141] M.H. Amer, Gene therapy for cancer: present status and future perspective,
Molecular and Cellular Therapies 2(1) (2014) 27.
[142] M.P. Gantier, B.R.G. Williams, The response of mammalian cells to double-stranded
RNA, Cytokine & Growth Factor Reviews 18(5) (2007) 363-371.
[143] T.M. Rana, Illuminating the silence: understanding the structure and function of
small RNAs, Nature Reviews Molecular Cell Biology 8(1) (2007) 23-36.
[144] L. Manche, S.R. Green, C. Schmedt, M.B. Mathews, Interactions between doublestranded RNA regulators and the protein kinase DAI, Mol Cell Biol 12(11) (1992) 5238-48.

152
[145] N.J. Caplen, S. Parrish, F. Imani, A. Fire, R.A. Morgan, Specific inhibition of gene
expression by small double-stranded RNAs in invertebrate and vertebrate systems,
Proceedings of the National Academy of Sciences 98(17) (2001) 9742.
[146] M. Izquierdo, Short interfering RNAs as a tool for cancer gene therapy, Cancer Gene
Therapy 12(3) (2005) 217-227.
[147] J. Conde, N. Artzi, Are RNAi and miRNA therapeutics truly dead?, Trends in
Biotechnology 33(3) (2015) 141-144.
[148] D. Ibraheem, A. Elaissari, H. Fessi, Gene therapy and DNA delivery systems,
International Journal of Pharmaceutics 459(1) (2014) 70-83.
[149] L. Huang, Y. Liu, In Vivo Delivery of RNAi with Lipid-Based Nanoparticles, Annual
Review of Biomedical Engineering 13(1) (2011) 507-530.
[150] S.-h. Hsu, B. Yu, X. Wang, Y. Lu, C.R. Schmidt, R.J. Lee, L.J. Lee, S.T. Jacob, K.
Ghoshal, Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to
murine liver tumor, Nanomedicine: Nanotechnology, Biology and Medicine 9(8) (2013)
1169-1180.
[151] Q. Pan, R. Cai, X. Liu, C. Qian, A novel strategy for cancer gene therapy: RNAi,
Chinese Science Bulletin 51(10) (2006) 1145-1151.
[152] H. Atkinson, R. Chalmers, Delivering the goods: viral and non-viral gene therapy
systems and the inherent limits on cargo DNA and internal sequences, Genetica 138(5)
(2010) 485-98.

153
[153] M. Ramamoorth, A. Narvekar, Non viral vectors in gene therapy- an overview, J
Clin Diagn Res 9(1) (2015) GE01-GE6.
[154] N. Nayerossadat, T. Maedeh, P.A. Ali, Viral and nonviral delivery systems for gene
delivery, Adv Biomed Res 1 (2012) 27-27.
[155] S.D. Li, L. Huang, Gene therapy progress and prospects: non-viral gene therapy by
systemic delivery, Gene Therapy 13(18) (2006) 1313-1319.
[156]

N.

Csaba,

M.

Köping-Höggård,

M.J.

Alonso,

Ionically

crosslinked

chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery,
International Journal of Pharmaceutics 382(1) (2009) 205-214.
[157] L. De Laporte, J. Cruz Rea, L.D. Shea, Design of modular non-viral gene therapy
vectors, Biomaterials 27(7) (2006) 947-954.
[158] M.R. Díaz, P.E. Vivas-Mejia, Nanoparticles as Drug Delivery Systems in Cancer
Medicine: Emphasis on RNAi-Containing Nanoliposomes, Pharmaceuticals 6(11) (2013)
1361-1380.
[159] J. Torrecilla, A. Rodríguez-Gascón, M.Á. Solinís, A. del Pozo-Rodríguez, Lipid
Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future
Perspectives, BioMed Research International 2014 (2014) 161794.
[160] J. Zhou, K.-T. Shum, J.C. Burnett, J.J. Rossi, Nanoparticle-Based Delivery of RNAi
Therapeutics: Progress and Challenges, Pharmaceuticals 6(1) (2013).

154
[161] D. Boraschi, P. Italiani, R. Palomba, P. Decuzzi, A. Duschl, B. Fadeel, S.M. Moghimi,
Nanoparticles and innate immunity: new perspectives on host defence, Seminars in
Immunology 34 (2017) 33-51.
[162] J.A. Wolff, D.B. Rozema, Breaking the Bonds: Non-viral Vectors Become Chemically
Dynamic, Molecular Therapy 16(1) (2008) 8-15.
[163] K.A. Whitehead, R. Langer, D.G. Anderson, Knocking down barriers: advances in
siRNA delivery, Nature Reviews Drug Discovery 8(2) (2009) 129-138.
[164] H. Kobayashi, R. Watanabe, P.L. Choyke, Improving conventional enhanced
permeability and retention (EPR) effects; what is the appropriate target?, Theranostics 4(1)
(2013) 81-89.
[165] C. Viallard, B. Larrivée, Tumor angiogenesis and vascular normalization: alternative
therapeutic targets, Angiogenesis 20(4) (2017) 409-426.
[166] J. Fang, H. Nakamura, H. Maeda, The EPR effect: Unique features of tumor blood
vessels for drug delivery, factors involved, and limitations and augmentation of the effect,
Advanced Drug Delivery Reviews 63(3) (2011) 136-151.
[167] T. Stylianopoulos, M.-Z. Poh, N. Insin, M.G. Bawendi, D. Fukumura, Lance L. Munn,
R.K. Jain, Diffusion of Particles in the Extracellular Matrix: The Effect of Repulsive
Electrostatic Interactions, Biophysical Journal 99(5) (2010) 1342-1349.
[168] M. Le Goas, F. Testard, O. Taché, N. Debou, B. Cambien, G. Carrot, J.-P. Renault,
How Do Surface Properties of Nanoparticles Influence Their Diffusion in the Extracellular

155
Matrix? A Model Study in Matrigel Using Polymer-Grafted Nanoparticles, Langmuir
36(35) (2020) 10460-10470.
[169] X. He, Y. Yang, L. Li, P. Zhang, H. Guo, N. Liu, X. Yang, F. Xu, Engineering
extracellular matrix to improve drug delivery for cancer therapy, Drug Discovery Today
25(9) (2020) 1727-1734.
[170] S.A. Smith, L.I. Selby, A.P.R. Johnston, G.K. Such, The Endosomal Escape of
Nanoparticles: Toward More Efficient Cellular Delivery, Bioconjugate Chemistry 30(2)
(2019) 263-272.
[171] C.M. Walsh, Grand challenges in cell death and survival: apoptosis vs. necroptosis,
Front Cell Dev Biol 2 (2014) 3-3.
[172] M.O. Hengartner, The biochemistry of apoptosis, Nature 407(6805) (2000) 770-776.
[173] P. Meier, A. Finch, G. Evan, Apoptosis in development, Nature 407(6805) (2000) 796801.
[174] S.W. Lowe, A.W. Lin, Apoptosis in cancer, Carcinogenesis 21(3) (2000) 485-495.
[175] R.J. Bold, P.M. Termuhlen, D.J. McConkey, Apoptosis, cancer and cancer therapy,
Surgical Oncology 6(3) (1997) 133-142.
[176] J.F.R. Kerr, A.H. Wyllie, A.R. Currie, Apoptosis: A Basic Biological Phenomenon
with Wideranging Implications in Tissue Kinetics, British Journal of Cancer 26(4) (1972)
239-257.

156
[177] G.M. COHEN, Caspases: the executioners of apoptosis, Biochemical Journal 326(1)
(1997) 1-16.
[178] J.F. Kerr, C.M. Winterford, B.V. Harmon, Apoptosis. Its significance in cancer and
cancer therapy, Cancer 73(8) (1994) 2013-26.
[179] S. Elmore, Apoptosis: A Review of Programmed Cell Death, Toxicologic Pathology
35(4) (2007) 495-516.
[180] S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri, T. Kamarul, Potential of
apoptotic pathway-targeted cancer therapeutic research: Where do we stand?, Cell Death
& Disease 7(1) (2016) e2058-e2058.
[181] S. Inoue, G. Browne, G. Melino, G.M. Cohen, Ordering of caspases in cells
undergoing apoptosis by the intrinsic pathway, Cell Death & Differentiation 16(7) (2009)
1053-1061.
[182] M. Movassagh, R.S.Y. Foo, Simplified apoptotic cascades, Heart Failure Reviews
13(2) (2008) 111-119.
[183] P.C. Ashe, M.D. Berry, Apoptotic signaling cascades, Progress in NeuroPsychopharmacology and Biological Psychiatry 27(2) (2003) 199-214.
[184] K.H. Khan, M. Blanco-Codesido, L.R. Molife, Cancer therapeutics: Targeting the
apoptotic pathway, Critical Reviews in Oncology/Hematology 90(3) (2014) 200-219.
[185] S. Fulda, K.M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer
chemotherapy, Oncogene 25(34) (2006) 4798-4811.

157
[186] R.S.Y. Wong, Apoptosis in cancer: from pathogenesis to treatment, Journal of
Experimental & Clinical Cancer Research 30(1) (2011) 87.
[187] S. Cory, J.M. Adams, The Bcl2 family: regulators of the cellular life-or-death switch,
Nature Reviews Cancer 2(9) (2002) 647-656.
[188] K.H. Vousden, K.M. Ryan, p53 and metabolism, Nature Reviews Cancer 9(10) (2009)
691-700.
[189] E. Meulmeester, A.G. Jochemsen, p53: A Guide to Apoptosis, Current Cancer Drug
Targets 8(2) (2008) 87-97.
[190] S. Ghavami, M. Hashemi, S.R. Ande, B. Yeganeh, W. Xiao, M. Eshraghi, C.J. Bus, K.
Kadkhoda, E. Wiechec, A.J. Halayko, M. Los, Apoptosis and cancer: mutations within
caspase genes, Journal of Medical Genetics 46(8) (2009) 497-510.
[191] A.J.M. Watson, Apoptosis and colorectal cancer, Gut 53(11) (2004) 1701.
[192] L. Yang, Y. Zhou, Y. Li, J. Zhou, Y. Wu, Y. Cui, G. Yang, Y. Hong, Mutations of p53
and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via
dysregulation of cell cycle and suppression of apoptosis in lung cancer cells, Cancer
Letters 357(2) (2015) 520-526.
[193] K. Fernald, M. Kurokawa, Evading apoptosis in cancer, Trends in Cell Biology 23(12)
(2013) 620-633.

158
[194] D. Landesman-Milo, M. Goldsmith, S. Leviatan Ben-Arye, B. Witenberg, E. Brown,
S. Leibovitch, S. Azriel, S. Tabak, V. Morad, D. Peer, Hyaluronan grafted lipid-based
nanoparticles as RNAi carriers for cancer cells, Cancer Letters 334(2) (2013) 221-227.
[195] B. Ballarín-González, M.F. Ebbesen, K.A. Howard, Polycation-based nanoparticles
for RNAi-mediated cancer treatment, Cancer Letters 352(1) (2014) 66-80.
[196] S.Y. Wu, G. Lopez-Berestein, G.A. Calin, A.K. Sood, RNAi Therapies: Drugging the
Undruggable, Science Translational Medicine 6(240) (2014) 240ps7.
[197] M. Wang, M. Thanou, Targeting nanoparticles to cancer, Pharmacological Research
62(2) (2010) 90-99.
[198] C.E. Nelson, J.R. Kintzing, A. Hanna, J.M. Shannon, M.K. Gupta, C.L. Duvall,
Balancing Cationic and Hydrophobic Content of PEGylated siRNA Polyplexes Enhances
Endosome Escape, Stability, Blood Circulation Time, and Bioactivity in Vivo, ACS Nano
7(10) (2013) 8870-8880.
[199] D.W. Malcolm, M.A.T. Freeberg, Y. Wang, K.R. Sims, H.A. Awad, D.S.W. Benoit,
Diblock

Copolymer

Hydrophobicity

Facilitates

Efficient

Gene

Silencing

and

Cytocompatible Nanoparticle-Mediated siRNA Delivery to Musculoskeletal Cell Types,
Biomacromolecules 18(11) (2017) 3753-3765.
[200] A. Neamnark, O. Suwantong, R.B. K. C, C.Y.M. Hsu, P. Supaphol, H. Uludağ,
Aliphatic Lipid Substitution on 2 kDa Polyethylenimine Improves Plasmid Delivery and
Transgene Expression, Molecular Pharmaceutics 6(6) (2009) 1798-1815.

159
[201] Z. Liu, Z. Zhang, C. Zhou, Y. Jiao, Hydrophobic modifications of cationic polymers
for gene delivery, Progress in Polymer Science 35(9) (2010) 1144-1162.
[202] M. Wang, H. Liu, L. Li, Y. Cheng, A fluorinated dendrimer achieves excellent gene
transfection efficacy at extremely low nitrogen to phosphorus ratios, Nature
Communications 5(1) (2014) 3053.
[203] M.C.Z. Kasuya, S. Nakano, R. Katayama, K. Hatanaka, Evaluation of the
hydrophobicity of perfluoroalkyl chains in amphiphilic compounds that are incorporated
into cell membrane, Journal of Fluorine Chemistry 132(3) (2011) 202-206.
[204] G. Chen, Y. Wang, A. Ullah, Y. Huai, Y. Xu, The effects of fluoroalkyl chain length
and density on siRNA delivery of bioreducible poly(amido amine)s, European Journal of
Pharmaceutical Sciences 152 (2020) 105433.
[205] C. Ge, J. Yang, S. Duan, Y. Liu, F. Meng, L. Yin, Fluorinated α-Helical Polypeptides
Synchronize Mucus Permeation and Cell Penetration toward Highly Efficient Pulmonary
siRNA Delivery against Acute Lung Injury, Nano Letters 20(3) (2020) 1738-1746.
[206] L. Xue, Y. Yan, P. Kos, X. Chen, D.J. Siegwart, PEI fluorination reduces toxicity and
promotes liver-targeted siRNA delivery, Drug Deliv Transl Res 11(1) (2021) 255-260.
[207] X. Cai, H. Zhu, Y. Zhang, Z. Gu, Highly Efficient and Safe Delivery of VEGF siRNA
by Bioreducible Fluorinated Peptide Dendrimers for Cancer Therapy, ACS Applied
Materials & Interfaces 9(11) (2017) 9402-9415.

160
[208] B. He, Y. Wang, N. Shao, H. Chang, Y. Cheng, Polymers modified with double-tailed
fluorous compounds for efficient DNA and siRNA delivery, Acta Biomaterialia 22 (2015)
111-119.
[209] R.A. Burrell, N. McGranahan, J. Bartek, C. Swanton, The causes and consequences
of genetic heterogeneity in cancer evolution, Nature 501(7467) (2013) 338-345.
[210] A.C. Palmer, P.K. Sorger, Combination Cancer Therapy Can Confer Benefit via
Patient-to-Patient Variability without Drug Additivity or Synergy, Cell 171(7) (2017) 16781691.e13.
[211] A. Jhaveri, P. Deshpande, V. Torchilin, Stimuli-sensitive nanopreparations for
combination cancer therapy, Journal of Controlled Release 190 (2014) 352-370.
[212] Q. Jiang, X. Chen, H. Liang, Y. Nie, R. Jin, M. Barz, D. Yue, Z. Gu, Multistage rocket:
integrational design of a prodrug-based siRNA delivery system with sequential release
for enhanced antitumor efficacy, Nanoscale Advances 1(2) (2019) 498-507.
[213] Y. Tian, S. Wang, B. Wang, J. Zhang, R. Jiang, W. Zhang, Overexpression of SSAT by
DENSPM treatment induces cell detachment and apoptosis in glioblastoma, Oncol Rep
27(4) (2012) 1227-1232.
[214] Y. Chen, D.L. Kramer, F. Li, C.W. Porter, Loss of inhibitor of apoptosis proteins as a
determinant of polyamine analog-induced apoptosis in human melanoma cells, Oncogene
22(32) (2003) 4964-4972.

161
[215] A. Pledgie-Tracy, M. Billam, A. Hacker, M.D. Sobolewski, P.M. Woster, Z. Zhang,
R.A. Casero, N.E. Davidson, The role of the polyamine catabolic enzymes SSAT and SMO
in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue
in human breast cancer cell lines, Cancer Chemotherapy and Pharmacology 65(6) (2010)
1067-1081.
[216] T. Takahashi, B. Sano, T. Nagata, H. Kato, Y. Sugiyama, K. Kunieda, M. Kimura, Y.
Okano, S. Saji, Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers,
Cancer Science 94(2) (2003) 148-152.
[217] K. Strebhardt, A. Ullrich, Targeting polo-like kinase 1 for cancer therapy, Nature
Reviews Cancer 6(4) (2006) 321-330.
[218] W. Weichert, M. Schmidt, J. Jacob, V. Gekeler, J. Langrehr, P. Neuhaus, M. Bahra, C.
Denkert, M. Dietel, G. Kristiansen, Overexpression of Polo-Like Kinase 1 Is a Common
and Early Event in Pancreatic Cancer, Pancreatology 5(2-3) (2005) 259-265.
[219] C. Zhang, X. Sun, Y. Ren, Y. Lou, J. Zhou, M. Liu, D. Li, Validation of Polo-like kinase
1 as a therapeutic target in pancreatic cancer cells, Cancer Biology & Therapy 13(12) (2012)
1214-1220.
[220] S. Ganesh, A.K. Iyer, D.V. Morrissey, M.M. Amiji, Hyaluronic acid based selfassembling nanosystems for CD44 target mediated siRNA delivery to solid tumors,
Biomaterials 34(13) (2013) 3489-3502.
[221] A. Mero, M. Campisi, Hyaluronic Acid Bioconjugates for the Delivery of Bioactive
Molecules, Polymers 6(2) (2014) 346-369.

162
[222] Y. Xie, T. Murray-Stewart, Y. Wang, F. Yu, J. Li, L.J. Marton, R.A. Casero, D. Oupický,
Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of
polyamine metabolism in combination cancer therapy, Journal of Controlled Release 246
(2017) 110-119.
[223] Y. Zhu, J. Li, S. Kanvinde, Z. Lin, S. Hazeldine, R.K. Singh, D. Oupický, SelfImmolative Polycations as Gene Delivery Vectors and Prodrugs Targeting Polyamine
Metabolism in Cancer, Molecular Pharmaceutics 12(2) (2015) 332-341.
[224] Y. Dong, Y. Zhu, J. Li, Q.-H. Zhou, C. Wu, D. Oupický, Synthesis of
Bisethylnorspermine Lipid Prodrug as Gene Delivery Vector Targeting Polyamine
Metabolism in Breast Cancer, Molecular Pharmaceutics 9(6) (2012) 1654-1664.
[225] M. Wang, Y. Cheng, Structure-activity relationships of fluorinated dendrimers in
DNA and siRNA delivery, Acta Biomaterialia 46 (2016) 204-210.
[226] G. Chen, K. Wang, Q. Hu, L. Ding, F. Yu, Z. Zhou, Y. Zhou, J. Li, M. Sun, D. Oupický,
Combining Fluorination and Bioreducibility for Improved siRNA Polyplex Delivery, ACS
Appl Mater Interfaces 9(5) (2017) 4457-4466.
[227] P.M. Kabra, H.K. Lee, W.P. Lubich, L.J. Marton, Solid-phase extraction and
determination of dansyl derivatives of unconjugated and acetylated polyamines by
reversed-phase liquid chromatography: Improved separation systems for polyamines in
cerebrospinal fluid, urine and tissue, Journal of Chromatography B: Biomedical Sciences
and Applications 380 (1986) 19-32.

163
[228] R. Ran, Y. Liu, H. Gao, Q. Kuang, Q. Zhang, J. Tang, K. Huang, X. Chen, Z. Zhang,
Q. He, Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated
hyaluronic acid for anti P-glycoprotein siRNA: A potential candidate for overcoming
multi-drug resistance, International Journal of Pharmaceutics 477(1) (2014) 590-600.
[229] Y. Wang, J. Li, Y. Chen, D. Oupický, Balancing polymer hydrophobicity for ligand
presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes, Biomater
Sci 3(7) (2015) 1114-23.
[230] D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein, T. Kissel, In vitro cytotoxicity testing
of polycations: influence of polymer structure on cell viability and hemolysis, Biomaterials
24(7) (2003) 1121-1131.
[231] G. Chen, K. Wang, Q. Hu, L. Ding, F. Yu, Z. Zhou, Y. Zhou, J. Li, M. Sun, D. Oupický,
Combining Fluorination and Bioreducibility for Improved siRNA Polyplex Delivery, ACS
Applied Materials & Interfaces 9(5) (2017) 4457-4466.
[232] H.Y. Seok, N. Sanoj Rejinold, K.M. Lekshmi, K. Cherukula, I.K. Park, Y.C. Kim, CD44
targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for
curcumin delivery to cancer cells: In vitro and in vivo evaluation, J Control Release 280
(2018) 20-30.
[233] X. Liu, R.L. Erikson, Polo-like kinase (Plk)1 depletion induces apoptosis in cancer
cells, Proceedings of the National Academy of Sciences 100(10) (2003) 5789.

164
[234] B. Spänkuch, E. Kurunci-Csacsko, M. Kaufmann, K. Strebhardt, Rational
combinations of siRNAs targeting Plk1 with breast cancer drugs, Oncogene 26(39) (2007)
5793-5807.
[235] H.C. Ha, P.M. Woster, J.D. Yager, R.A. Casero, The role of polyamine catabolism in
polyamine analogue-induced programmed cell death, Proceedings of the National
Academy of Sciences 94(21) (1997) 11557-11562.
[236] Y. Xie, Y. Hang, Y. Wang, R. Sleightholm, D.R. Prajapati, J. Bader, A. Yu, W. Tang,
L. Jaramillo, J. Li, R.K. Singh, D. Oupický, Stromal Modulation and Treatment of
Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA
Nanotherapy, ACS Nano 14(1) (2020) 255-271.
[237] Y. Hang, S. Tang, W. Tang, D. Větvička, C. Zhang, Y. Xie, F. Yu, A. Yu, D. Sil, J. Li,
R.K. Singh, D. Oupický, Polycation fluorination improves intraperitoneal siRNA delivery
in metastatic pancreatic cancer, Journal of Controlled Release 333 (2021) 139-150.
[238] R.J. Bergeron, A.H. Neims, J.S. McManis, T.R. Hawthorne, J.R. Vinson, R. Bortell, M.J.
Ingeno, Synthetic polyamine analogues as antineoplastics, J Med Chem 31(6) (1988) 118390.
[239] R.L. Siegel, K.D. Miller, A. Goding Sauer, S.A. Fedewa, L.F. Butterly, J.C. Anderson,
A. Cercek, R.A. Smith, A. Jemal, Colorectal cancer statistics, 2020, CA: A Cancer Journal
for Clinicians 70(3) (2020) 145-164.
[240] M. Bretthauer, Colorectal cancer screening, Journal of Internal Medicine 270(2) (2011)
87-98.

165
[241] I.A. Issa, M. Noureddine, Colorectal cancer screening: An updated review of the
available options, World J Gastroenterol 23(28) (2017) 5086-5096.
[242] P. Favoriti, G. Carbone, M. Greco, F. Pirozzi, R.E. Pirozzi, F. Corcione, Worldwide
burden of colorectal cancer: a review, Updates Surg 68(1) (2016) 7-11.
[243] A.R. Marley, H. Nan, Epidemiology of colorectal cancer, Int J Mol Epidemiol Genet
7(3) (2016) 105-114.
[244] P. Rychahou, F. Haque, Y. Shu, Y. Zaytseva, H.L. Weiss, E.Y. Lee, W. Mustain, J.
Valentino, P. Guo, B.M. Evers, Delivery of RNA Nanoparticles into Colorectal Cancer
Metastases Following Systemic Administration, ACS Nano 9(2) (2015) 1108-1116.
[245] F. Di Fiore, F. Blanchard, F. Charbonnier, F. Le Pessot, A. Lamy, M.P. Galais, L. Bastit,
A. Killian, R. Sesboüé, J.J. Tuech, A.M. Queuniet, B. Paillot, J.C. Sabourin, F. Michot, P.
Michel, T. Frebourg, Clinical relevance of KRAS mutation detection in metastatic
colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer 96(8)
(2007) 1166-1169.
[246] J. Tie, L. Lipton, J. Desai, P. Gibbs, R.N. Jorissen, M. Christie, K.J. Drummond, B.N.J.
Thomson, V. Usatoff, P.M. Evans, A.W. Pick, S. Knight, P.W.G. Carne, R. Berry, A.
Polglase, P. McMurrick, Q. Zhao, D. Busam, R.L. Strausberg, E. Domingo, I.P.M.
Tomlinson, R. Midgley, D. Kerr, O.M. Sieber, <em>KRAS</em> Mutation Is Associated
with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer, Clinical
Cancer Research 17(5) (2011) 1122-1130.

166
[247] C.P. Vaughn, S.D. ZoBell, L.V. Furtado, C.L. Baker, W.S. Samowitz, Frequency of
KRAS, BRAF, and NRAS mutations in colorectal cancer, Genes, Chromosomes and Cancer
50(5) (2011) 307-312.
[248] A. Lièvre, J.-B. Bachet, D. Le Corre, V. Boige, B. Landi, J.-F. Emile, J.-F. Côté, G.
Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig,
<em>KRAS</em> Mutation Status Is Predictive of Response to Cetuximab Therapy in
Colorectal Cancer, Cancer Research 66(8) (2006) 3992-3995.
[249] K.L. Bryant, J.D. Mancias, A.C. Kimmelman, C.J. Der, KRAS: feeding pancreatic
cancer proliferation, Trends in Biochemical Sciences 39(2) (2014) 91-100.
[250] D. Kessler, M. Gmachl, A. Mantoulidis, L.J. Martin, A. Zoephel, M. Mayer, A. Gollner,
D. Covini, S. Fischer, T. Gerstberger, T. Gmaschitz, C. Goodwin, P. Greb, D. Häring, W.
Hela, J. Hoffmann, J. Karolyi-Oezguer, P. Knesl, S. Kornigg, M. Koegl, R. Kousek, L.
Lamarre, F. Moser, S. Munico-Martinez, C. Peinsipp, J. Phan, J. Rinnenthal, J. Sai, C.
Salamon, Y. Scherbantin, K. Schipany, R. Schnitzer, A. Schrenk, B. Sharps, G. Siszler, Q.
Sun, A. Waterson, B. Wolkerstorfer, M. Zeeb, M. Pearson, S.W. Fesik, D.B. McConnell,
Drugging an undruggable pocket on KRAS, Proceedings of the National Academy of
Sciences 116(32) (2019) 15823-15829.
[251] D. Uprety, A.A. Adjei, KRAS: From undruggable to a druggable Cancer Target,
Cancer Treatment Reviews 89 (2020).
[252] M.A. Matzke, J.A. Birchler, RNAi-mediated pathways in the nucleus, Nature
Reviews Genetics 6(1) (2005) 24-35.

167
[253] E. Alaaeldin, A.S. Abu Lila, N. Moriyoshi, H.A. Sarhan, T. Ishida, K.A. Khaled, H.
Kiwada, The Co-Delivery of Oxaliplatin Abrogates the Immunogenic Response to
PEGylated siRNA-Lipoplex, Pharmaceutical Research 30(9) (2013) 2344-2354.
[254] A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, G. Fisch, S. Dames, K. Löffler,
M. Fechtner, W. Arnold, K. Giese, A. Klippel, J. Kaufmann, A novel siRNA-lipoplex
technology for RNA interference in the mouse vascular endothelium, Gene Therapy 13(16)
(2006) 1222-1234.
[255] D. Scherman, A. Rousseau, P. Bigey, V. Escriou, Genetic pharmacology: progresses
in siRNA delivery and therapeutic applications, Gene Therapy 24(3) (2017) 151-156.
[256] O. Naksuriya, S. Okonogi, R.M. Schiffelers, W.E. Hennink, Curcumin
nanoformulations: A review of pharmaceutical properties and preclinical studies and
clinical data related to cancer treatment, Biomaterials 35(10) (2014) 3365-3383.
[257] S. Shishodia, M.M. Chaturvedi, B.B. Aggarwal, Role of Curcumin in Cancer Therapy,
Current Problems in Cancer 31(4) (2007) 243-305.
[258] C. Kantara, M. Connell, S. Sarkar, S. Moya, R. Ullrich, P. Singh, Curcumin Promotes
Autophagic Survival of a Subset of Colon Cancer Stem Cells, Which Are Ablated by
DCLK1-siRNA, Cancer Research 74(9) (2014) 2487.
[259] T. Murray-Stewart, R.A. Casero, Regulation of Polyamine Metabolism by Curcumin
for Cancer Prevention and Therapy, Med Sci (Basel) 5(4) (2017) 38.

168
[260] T. Murray-Stewart, M. Dunworth, Y. Lui, F.M. Giardiello, P.M. Woster, R.A. Casero,
Jr., Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells
to antitumor polyamine-targeted therapies, PLOS ONE 13(8) (2018) e0202677.
[261]

N.

Babbar,

Eugene W.

Gerner,

Robert A.

Casero,

Jr,

Induction

of

spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells,
Biochemical Journal 394(1) (2006) 317-324.
[262] A. Coker-Gurkan, M. Celik, M. Ugur, E.-D. Arisan, P. Obakan-Yerlikaya, Z.B. Durdu,
N. Palavan-Unsal, Curcumin inhibits autocrine growth hormone-mediated invasion and
metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells,
Amino Acids 50(8) (2018) 1045-1069.
[263] Y.-J. Wang, M.-H. Pan, A.-L. Cheng, L.-I. Lin, Y.-S. Ho, C.-Y. Hsieh, J.-K. Lin, Stability
of curcumin in buffer solutions and characterization of its degradation products, Journal
of Pharmaceutical and Biomedical Analysis 15(12) (1997) 1867-1876.
[264] K.-Y. Yang, L.-C. Lin, T.-Y. Tseng, S.-C. Wang, T.-H. Tsai, Oral bioavailability of
curcumin in rat and the herbal analysis from Curcuma longa by LC–MS/MS, Journal of
Chromatography B 853(1) (2007) 183-189.
[265] G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, P.S.S.R. Srinivas, Influence of
Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers, Planta
Med 64(04) (1998) 353-356.

169
[266] Y. Chen, Q. Wu, Z. Zhang, L. Yuan, X. Liu, L. Zhou, Preparation of CurcuminLoaded Liposomes and Evaluation of Their Skin Permeation and Pharmacodynamics,
Molecules 17(5) (2012) 5972-5987.
[267] X. Li, T. Chen, L. Xu, Z. Zhang, L. Li, H. Chen, Preparation of Curcumin Micelles
and the In Vitro and In Vivo Evaluation for Cancer Therapy, Journal of Biomedical
Nanotechnology 10(8) (2014) 1458-1468.
[268] N. Patel, L. Ghali, I. Roitt, L.P. Munoz, R. Bayford, Exploiting the efficacy of Tyro3
and folate receptors to enhance the delivery of gold nanoparticles into colorectal cancer
cells in vitro, Nanoscale Advances 3(18) (2021) 5373-5386.
[269] S.-J. Yang, F.-H. Lin, K.-C. Tsai, M.-F. Wei, H.-M. Tsai, J.-M. Wong, M.-J. Shieh, Folic
Acid-Conjugated Chitosan Nanoparticles Enhanced Protoporphyrin IX Accumulation in
Colorectal Cancer Cells, Bioconjugate Chemistry 21(4) (2010) 679-689.
[270] A.A. Lohade, R.R. Jain, K. Iyer, S.K. Roy, H.H. Shimpi, Y. Pawar, M.G.R. Rajan, M.D.
Menon, A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer
Targeting, AAPS PharmSciTech 17(6) (2016) 1298-1311.
[271] Z.-Y. He, X.-W. Wei, M. Luo, S.-T. Luo, Y. Yang, Y.-Y. Yu, Y. Chen, C.-C. Ma, X. Liang,
F.-C. Guo, T.-H. Ye, H.-S. Shi, G.-B. Shen, W. Wang, F.-M. Gong, G. He, L. Yang, X. Zhao,
X.-R. Song, Y.-Q. Wei, Folate-linked lipoplexes for short hairpin RNA targeting claudin-3
delivery in ovarian cancer xenografts, Journal of Controlled Release 172(3) (2013) 679-689.
[272] M. Wang, H. Hu, Y. Sun, L. Qiu, J. Zhang, G. Guan, X. Zhao, M. Qiao, L. Cheng, L.
Cheng, D. Chen, A pH-sensitive gene delivery system based on folic acid-PEG-chitosan -

170
PAMAM-plasmid DNA complexes for cancer cell targeting, Biomaterials 34(38) (2013)
10120-32.
[273] C.F. Chignell, P. Bilski, K.J. Reszka, A.G. Motten, R.H. Sik, T.A. Dahl, Spectral and
photochemical properties of curcumin, Photochem Photobiol 59(3) (1994) 295-302.
[274] C. Fella, G.F. Walker, M. Ogris, E. Wagner, Amine-reactive pyridylhydrazone-based
PEG reagents for pH-reversible PEI polyplex shielding, European Journal of
Pharmaceutical Sciences 34(4) (2008) 309-320.
[275] Y. Vachutinsky, K. Kataoka, PEG-based Polyplex Design for Gene and Nucleotide
Delivery, Israel Journal of Chemistry 50(2) (2010) 175-184.
[276] M.Z. Kamran, P. Patil, R.P. Gude, Role of STAT3 in Cancer Metastasis and
Translational Advances, BioMed Research International 2013 (2013) 421821.
[277] Z.C. Soe, B.K. Poudel, H.T. Nguyen, R.K. Thapa, W. Ou, M. Gautam, K. Poudel, S.G.
Jin, J.-H. Jeong, S.K. Ku, H.-G. Choi, C.S. Yong, J.O. Kim, Folate-targeted nanostructured
chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to
colorectal cancer cells, Asian Journal of Pharmaceutical Sciences 14(1) (2019) 40-51.

